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The absence of reliable predicting factors for risk stratification resulted in similar treatment 
schedules for all osteosarcoma patients. In fact, there are no adaptations in post-operative 
therapy in patients with poor response to the pre-operative treatment. As such, it appears 
that we have reached the limit in the survival of osteosarcoma patients achievable with 
currently available chemotherapy. Several new chemotherapeutic drugs have been inves-
tigated over the past three decades. However, only few agents have shown clinical ben-
efit. The use of monoclonal antibodies such as trastuzumab, which targets the epidermal 
growth factor receptor 2, has been studied in a phase II trial showing no improvement in 
outcome19. The effect of interferon alpha (IFN α) is currently studied in the EURAMOS 1 
trial. Preliminary data show a 3-year DFS of 77% in patients who were randomized to have 
interferon injections compared to 74% of those who were randomized to have chemother-
apy alone20. Treatment with bisphosphonates such as pamidronate or zoledronic acid in 
addition to chemotherapy is only applied to a hand full of patients and the clinical benefit 
of these agents need to be studied in a prospective randomized trial21,22. As the incidence 
of osteosarcoma is between 3 and 4.5 cases per million, it will take several years to in-
clude a large number of patients in a prospective trial to study the efficacy of these new 
agents. Furthermore, the a priori knowledge of which patients will benefit from new agents 
will help to define new strategies in order to improve outcome and decrease the burden 
of late effects. We hypothesized that pharmacogenetics may help to stratify patient into 
good responders and bad responders. More insight in the genetic determinants involved in 
drug response may help in designing more effective therapeutic approaches, e.g. targeted 
cancer therapy for patients not responding on standard therapy (Figure I). 
Osteosarcoma
Osteosarcoma is the most common primary tumor of the bone, which may occur at all 
ages but is seen predominantly in adolescents. Nevertheless, it is still a rare disease with a 
worldwide incidence rate of 3-4 cases per million per year1. Untreated, osteosarcoma is fa-
tal. Aggressive local growth and the tendency to metastasize mark its course. In the 1970s 
when surgery was the only treatment option, the prognosis for patients with osteosarcoma 
was poor, with long-term survival rates of less than 20%2. Today, therapy is changed to 
a multi-disciplinary approach, focusing on both local and systemic manifestations of os-
teosarcoma, incorporating surgery and chemotherapy. The use of this multi-disciplinary 
approach has resulted in survival rates of 60-65% since the late 1980s3. Whereas in other 
forms of cancer clear progress has been made in the previous decades, either by the use of 
new drugs or by the ability of risk stratification and subsequently treatment adjustments4, 
in patients with osteosarcoma no substantial improvement in disease free survival (DFS) 
has been achieved.
The specific roles of various chemotherapeutic agents in the treatment of osteosarcoma 
have been the subject of many studies in the last three decades. There is considerable 
agreement among specialists about the main components: cisplatin and doxorubicin which 
are the most active drugs and are virtually part of every treatment protocol since the 
1980s. Several studies have reported superior results using regimens containing these 
two drugs in addition to other agents such as methotrexate (MTX) and ifosfamide5-7. In the 
recent study trial of the European and American Osteosarcoma Study Group (EURAMOS), 
the combination of cisplatin, doxorubicin and high-dose methotrexate forms the standard 
treatment arm. The addition of ifosfamide with or without etoposide remains controver-
sial8-10 and is now being studied in a randomized setting in EURAMOS I. 
The ratio to introduce pre-operative chemotherapy in the late 1970s was based 
on the development of limb-sparing procedures. Pre-operative chemotherapy was 
used to bridge the gap between biopsy and resection as the manufacturing of cus-
tom made limb-sparing endoprotheses took several weeks11. With this approach, it 
is now possible to evaluate the efficacy of the treatment by assessing the response of 
the tumor to pre-operative therapy12. Numerous studies have shown a strong cor-
relation between tumor necrosis greater than 90% and a better pro gnosis12-16. 
This histological response is currently the most sensitive indicator of survival. The contri-
bution of traditional prognostic factors like age, gender, tumor site and size were subject 
of numerous studies but results are contradictive and therefore there is no consensus 
whether these prognostic variables might be used to stratify patients before the onset of 
therapy17. The prognostic value of histological response led to the hypothesis that inten-
sification of chemotherapy may increase survival in poor responders. However, intensifi-
cation of preoperative treatment did not improve long-term outcomes18. Moreover, when 
preoperative therapy was lengthened, the histological response loses its prognostic value18. 
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Pharmacogenet i cs
Using pharmacogenetics, we investigated inherited genetic variations which might affect 
individual responses to drugs. Many different methods are used to investigate the role of 
genetic variants in genes coding for proteins involved in the metabolism of drugs used for 
a certain disease. These include candidate gene approaches, pathway-gene approach and 
genome wide association studies (GWAS). Each of these techniques is useful in a certain 
way but has also limitations (Figure II).
Figure II. Different methods to investigate the role of genetic variants in drug related genes.
       Single gene approach
x Analyses favourite candidate gene 
x Requires a large cohort to test the 
association 
x Carries the risk of not finding an 
association 
x Provides proof of principle if an 
association is found 
       Genome wide approach
x Analyses the whole genome 
x Requires larger cohorts to test 
association 
x Biological meaning is difficult to 
assess because this approach 
carries a risk of false positives 
x Might identify new associations 
       Candidate pathway gene approach
x Analyses several functionally related 
candidate genes
x Requires a smaller cohort to test the 
association 
x Carries the risk of missing important 
genes 
x Provides a more biologically 
meaningful association 
Drug related 
phenotype
The candidate gene approach is a hypothesis driven method that investigates genetic vari-
ants in genes known to be associated with the trait of interest e.g. metabolism of the used 
medication. However, replication studies often show inconsistent results making it difficult 
to interpret the clinical value of these studies23-28, e.g. these problems may be addressed 
by combining results from different studies in a meta-analysis. GWAS on the other hand, 
is a hypothesis free approach, testing thousands/millions of genetic variants in one test 
that is aimed to discover genes not previously known to be associated with the trait. It is 
a useful method to determine the most significant single nucleotide polymorphisms (SNPs) 
associated with a certain phenotype in a high-density set of SNPs. A disadvantage of the 
GWAS however, is the discovery of false positive associations and the often weak statistical 
signals. When using the GWAS technique, one needs large patient cohorts for discovery, 
and validation. As the incidence of osteosarcoma patients is low, such large cohorts are 
not available. For this reason, we performed a pharmacogenetic pathway approach in-
Figure I. Application of pharmacogenetics to stratify the individual patient
Patients with same diagnosis 
Alternative treatment 
Non-responders Toxic-responders
Standard treatment 
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With a 5-year overall survival of approximately 50-60%, archived histological specimens 
were often the only accessible source of biological material. Chapter 4 describes the pro-
cess of isolating germ-line DNA from decalcified formalin-fixed, paraffin-embedded (FFPE) 
tissue. The most active drugs in the treatment of osteosarcoma are cisplatin, doxorubicin 
and high-dose MTX. 
The use of multi-agent therapy led to an enhanced survival of osteosarcoma patients but, 
this concept is unfortunately also associated with acute and long-term toxicity. In the 
treatment of high-dose MTX a threshold peak level is needed to achieve good response on 
chemotherapy. On the other hand, high concentration levels lead to an increased risk of 
toxicity. In chapter 5 we describe the influence of genetic variation in the elimination of 
MTX. We investigated if SNPs in genes involved in the folate pathway, the key pathway in 
the processing of MTX, are associated with delayed MTX elimination and/or MTX induced 
toxicity. 
One of the most common side effects of MTX is hepatotoxicity. The most studied SNP with re-
spect to MTX-induced hepatotoxicity is the 677C>T variant in the methylenetetrahydrofolate 
reductase (MTHFR) gene. However, not all studies have been able to link presence of the 677T 
allele to an increased risk of MTX-induced toxicity. For this reason, we performed a meta-anal-
ysis including 1044 cancer patients which is described in chapter 6.
Hearing loss is one of the most common long-term side effects of cisplatin. Patients with osteosar-
coma are more prone to ototoxicity due to the high cumulative dose of cisplatin during treatment. 
Recently, a candidate gene study suggested that genetic variants in the genes encoding thiopu-
rine S-methyltransferase (TPMT) and catechol O-methyltransferase (COMT) can predict the de-
velopment of cisplatin-induced ototoxicity36. A recently published study37 however, failed to vali-
date these findings and showed inconsistent results. The aim of the study described in chapter 7 
was to provide a clearer picture of the genetic impact of TPMT and COMT variants on devel-
oping cisplatin-induced ototoxicity by performing the largest meta-analysis to date including 
664 patients with cancer.
Treatment of patients with osteosarcoma seems to have substantial shortcomings in op-
timal strategies compared to other types of cancer. The most consistent prognostic factor 
for outcome is the presence of metastatic lesions at time of diagnosis. However, treatment 
management of this patient group follows the same principles as the treatment of patients 
with localized disease. Several studies have reported that histologic response after neo-
adjuvant therapy is of prognostic value for survival, but it cannot be assessed at time of 
diagnosis. Further advances in treatment will however be dependent on reliable predicting 
factors for risk stratification. In chapter 8 we report the influence of genetic variants on 
outcome. We hypothesized that by identifying the genetic variants in genes relevant for 
the response of chemotherapeutic treatment it may be possible to stratify treatment of 
patients immediately after diagnosis and offer the possibility to improve treatment and 
subsequently progression free survival of patients with osteosarcoma. 
A general discussion of the studies that are presented in this thesis is given in chapter 9.
cluding the pathways of the three main chemotherapeutic drugs used in the treatment of 
osteosarcoma patients in the past three decades; pharmacogenetic studies have already 
been described in adults with cancer leading even to adjustment of therapy in patients 
with breast cancer29-31. In childhood cancer, studies have been performed investigating the 
presence of SNPs of one candidate gene involved in the metabolism of one drug. One of 
the first results of these pharmacogenetic studies was the identification of a polymorphism 
in the gene thiopurine-S-methyltransferase (TPMT) that were related to therapy outcome 
in children with acute lymphoblastic leukemia (ALL)32.
As doxorubicin and cisplatin are the cornerstones of the treatment of osteosarcoma pa-
tients, we primarily focused on genes and genetic variants involved in the metabolism 
of these two drugs. The third drug often used in the treatment of osteosarcoma is MTX. 
Although results are not conclusive, it is suggested that at least in pediatric patients with 
osteosarcoma MTX plays an important role33. For this reason MTX is included in many pro-
tocols and the influence of pharmacogenetic factors in the pharmacological effect of MTX 
(pharmacokinetics and dynamics) is also subject of this thesis.
Objectives and outline of this thesis
The main objective of this thesis was to define a patient’s genetic profile predicting the 
response to therapy, with the ultimate goal to develop individualized, improved, treatment 
schedules for patients with osteosarcoma based on their genetic profiles. In addition, we 
tried to identify patients with an increased risk of developing treatment-related toxicity, 
e.g. ototoxicity and hepatotoxicity. In future studies these profiles might be used prospec-
tively, leading to adjustment of therapy without jeopardizing outcome. 
In chapter 2 we describe a retrospective analysis of pediatric patients with osteosarcoma 
and compared this to adult patients to study whether age has an influence on outcome. It 
has been described that there are expression changes in enzymes during aging. E.g., the 
enzymes of the p450 cytochromes (CYPs) system change markedly during the fetal period 
to the first year of life34. However, limited data are available on the expression changes ef-
fect between the age of 10 and 40 years, where osteosarcoma is predominantly diagnosed. 
A recently published study describes age related variation in drug transporter expres-
sion showing significantly lower expressions levels in all pediatric age groups compared 
to adults35. In addition, other pharmacological processes like absorption and excretion of 
drugs might differ during growth and development. This might influence the response to 
the chemotherapeutics given to patients in both efficacy and toxicity. 
The rareness of the disease forced us to include patients over a lengthy period of 30 years. 
Hence, in chapter 3 we describe survival trends and analysed the occurrence of long term 
toxicity over the last three decades to gain more insight what could have influenced out-
come in our patient group.
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In t roduct ion
Osteosarcoma is the most common primary tumor of the bone, which may occur at all 
ages but is seen predominantly in adolescents. Nevertheless, it is still a rare disease with a 
worldwide incidence rate of 3-4 cases per million per year1. Until the seventies, osteosarco-
ma had a very poor prognosis. Major progress was made with the introduction of adjuvant 
chemotherapy. Disease-free survival (DFS) rates increased from below 20% with surgery 
only to more than 40% with adjuvant chemotherapy2-4. Unfortunately, osteosarcoma is 
relatively resistant to many chemotherapeutics leading to a rather short list of effective 
drugs. The majority of the currently used treatment protocols are based on a combination 
of doxorubicin, cisplatin, methotrexate (MTX), and/or ifosfamide. Introduction of neoadju-
vant and adjuvant chemotherapy in the context of more intensive multiagent regimens has 
led to a survival of 60%5-8. However, it seems that survival rates have reached a plateau. 
Treatment related toxicity and mortality are the main limiting factors allowing no further 
treatment intensification. E.g., higher dosage of chemotherapy resulted in more long-term 
complications like cardiac failure9,10. 
Identification of patients with a favorable prognosis and those with a poor prognosis may 
be used to adjust treatment schedules. Generally accepted prognostic factors for survival 
of osteosarcoma are presence of metastases at time of diagnosis, histologic response to 
neoadjuvant chemotherapy and adequate surgical margins. The prognostic relevance of 
other factors such as tumor site and size, histologic subtype, elevated alkaline phosphatase 
(AP), elevated lactate dehydrogenese (LDH) and age are still controversial. Although age 
at time of diagnosis is a well-known prognostic factor in many different malignancies11,12, 
its relevance in the treatment of osteosarcoma patients is still not clear. There are several 
reports in literature about outcome of patients older than 40 years versus younger than 
40 years showing that age above 40 years is associated with a worse outcome13,14. How-
ever, highest incidence of osteosarcoma is seen in the younger patient group with a peak 
incidence at the adolescence age. There are some reports showing a favorable outcome 
for osteosarcoma patients below 14 years15-17 others report that the outcome is worse for 
this same age group18,19. Because of these contradictive reports, the relevance of age as 
prognostic factor in patients with osteosarcoma needs further elucidation. For this reason, 
we retrospectively analyzed the role of age in a cohort of patients up to the age of 40 years, 
with both, metastatic and non-metastatic osteosarcoma. 
Pa t ients  and Methods
Pat ients
We treated 112 osteosarcoma patients in our institution between 1979 and 2008 with 
newly diagnosed, high-grade osteosarcoma. All patients were aged below 40 years. None 
of the patients was known with Paget’s disease. We excluded two patients with a histo-
Abst rac t
Age at diagnosis is a well-known prognostic factor in many different malignancies; its sig-
nificance for patients with osteosarcoma is however controversial. To gain more insight in 
the prognostic role of age, we performed a retrospective study at our institute. We included 
102 patients with de-novo osteosarcoma and formed three age groups to evaluate age 
specific survival rates: ≤14 years, 15-19 years and 20-40 years. Differences in outcome 
between patients aged 15-19 years treated at either the pediatric department or the adult 
department of oncology were evaluated. The 5-year overall survival rate (OS) of the whole 
population was 53.5% ±1.5%. OS of 70.6% ±0.8% was seen in patients ≤14 years old, 
52.5% ±1.1% in patients 15-19 years old and 33.3% ±0.9% in the patients aged 20-40 
years (p=0.01). Significant differences were observed with regard to stage at presentation 
(higher in older age groups), size of the tumor (larger in younger age groups) and histo-
logical response (more good responders in younger age groups). No significant difference 
was seen between outcomes of patients aged 15-19 years treated at the pediatric or adult 
oncology department. In conclusion, younger patients have a significantly better outcome 
than older patients. 
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Surgery
The surgical procedure depended on the location and extension of the tumor. Surgical mar-
gins were categorized following the criteria defined by Enneking as radical, wide, marginal 
and inadequate if margins were contaminated23. 
S ta t i s t i ca l  Ana lys i s
Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Mei-
er method24. OS was defined as the interval between diagnosis and death from any cause. 
Patients alive at the date of last follow-up were censored at that time point. DFS was 
defined as the interval between diagnosis and disease progression/recurrence. Patients 
without disease recurrence at the date of last follow-up were censored at that date. 
Survival and potential prognostic variables were analyzed using cox regression. The clinical 
characteristics examined included age at diagnosis, gender, site and size of the primary tu-
mor, histological type, presence of metastases, serum alkaline phosphatase (AF) level and 
serum lactate dehydrogenase (LDH) level. Treatment characteristics examined included 
chemotherapy, histological response, type of surgery and surgical margins. Factors found 
to influence prognosis by univariate analysis were analyzed by stepwise multivariate anal-
ysis using Cox’s proportional hazard regression model25. All analyses were performed using 
SPSS statistical analysis software (version 16.0, SPSS Inc, Chicago, IL).
ry of exposure to radiation due to prior malignancy and 8 patients with an incomplete 
dataset. In total, 102 patients were included in this analysis. Median age at diagnose 
was 17.8 years ranging from 4.5 to 39.5 years. Consistent with previous reports in the 
literature16,17,20 different age groups were defined starting with an age group ≤14 years. 
Subsequently a second group aged 15-19 years was defined. The third group consisted 
of patients aged 20-40 years. Recently, studies in adolescents with acute lymphoblastic 
leukemia (ALL) indicated that patients treated in pediatric departments had a higher prob-
ability of survival compared to those treated in adult departments21. To evaluate whether 
outcome in patients with osteosarcoma is related to treatment at a pediatric or adult de-
partment, this was studied in the patients with age between 15-19 years treated either at 
the department of pediatrics or treated at the department of medical oncology.
Treatment
Chemotherapy
Treatment was performed according to the protocol used at time of enrollment. From 1979 
to 2008, four consecutive protocols were used (Table I): EORTC 20781, EORTC 80831, 
EORTC 80931, and Euramos. 
Table I Cumulative Dose per protocol
 Doxorubicin mg/m2 Cisplatin mg/m2 Methotrexate g/m2
Protocol reg A reg B reg A reg B reg A reg B
EORTC 20781 420 420 - - 42 42
EORTC 80831 450 300 600 400 - 36
EORTC 80931 450   450* 600   600* - -
EURAMOS 450 450 480 480 144 144
*G-CSF, granulocyte-colony stimulating factor 
Treatment  ad jus tments
Reduction of chemotherapy was defined as more than 15% reduction of chemotherapy as 
compared to the planned cumulative dosage. 
His to log ica l  response
In patients treated with neoadjuvant chemotherapy, the histological response of the tumor 
was determined by evaluating the percentage of tumor necrosis in the removed material. 
The response to preoperative chemotherapy was defined ‘good’ if the amount of viable 
tumor was reports as less than 10% of the tumor area and ‘poor’ in the remaining cases. 
This is according the international criteria as defined by Rosen et al22.
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Table III. Patient Characteristics and Overall Survival (OS) (N=102)
Variables Number of  patients
5-year OS 
(%) p-Value
a
Sex  
 Female 47 56.5 -
 Male 55 49.1 0.156
Age  
 ≤ 14 years 34 70.6 -
 15-19 years 41 52.5 0.113
 > 20 years 27 33.3 0.004
Alkaline phosphatase*  
 Normal 39 64.1 -
 Elevated 55 51.9 0.115
Lactate dehydrogenase*  
 Normal 11 54.4 -
 Elevated 74 56.8 0.780
Maximal tumor length*  
 < 10 cm 44 56.8 -
 > 10 cm 46 51.1 0.294
Primary site  
 Extremities 93 56.5 -
 Axial 9 22.2 0.003
Location*  
 Humerus 7 71.4 -
 Tibia 20 60.0 0.53
 Femur 59 54.2 0.47
Histologic subtype*  
 Chondroblastic 11 54.5 -
 Osteoblastic 63 51.6 0.975
 Fibroblastic 6 50.0 0.822
Stage  
 Local 81 58.8 - 
 Metastatic 21 33.3 0.011
* not all data available
a  Calculated using cox regression
Resu l t s
Pat ients
The median follow-up was 5.6 years (range 2.4 to 30 years). The 5-year OS was 53.5% 
±1.5% and the 5-year DFS was 47.1% ±1.6%. All deaths (N=49) were related to osteo-
sarcoma with 17 deaths due to progression of the disease, two patients died after local 
recurrence and 30 after distant metastases (lung: N=24, other: N=4, both: N=2). 
As mentioned before, patients were divided in three subgroups regarding age. The age 
groups differed not significantly in the distribution of clinical and treatment related vari-
ables as is shown in Table II. Interestingly, patients ≤14 years had less frequently me-
tastases at diagnosis compared to older patients (8.8% vs. 25.9%, p=0.07), but were at 
the same time more likely to have tumors >10 cm (55.8% vs. 26.0%, p=0.053). Both 
having metastasis and/or having a tumor of more than 10 cm is associated with a worse 
outcome13,26. Regarding tumor location in the axial skeleton which is also associated with 
a poorer outcome, the number of cases arising from these sites in this series is greater in 
the older group but not statistically different (5.9% vs. 14.8%, p=0.24, Table II and III).
Table II. Patient characteristics according to age
Variables
≤ 14 years 15-19 years > 20 years
(N=34) (N=41)  (N=27)
% % %
Female 50.0 44.0 40.7
Femur 61.8 51.2 63.0
Humerus 14.7 4.9 7.4
Axial skeleton 5.9 7.3 14.8
Presence of metastases at diagnosis 8.8 26.8 25.9
Elevated alkaline phosphatase* 60.7 63.4 42.3
Tumor size > 10 cm 67.9 39.0 26.0
Good responders 26.9 5.9 9.5
Amputation/Rotationplasty** 74.2 39.4 34.6
Limb-sparing resection** 25.8 60.5 65.4
Marginal surgical margine* 22.6 29.7 32.0
Local recurrence 8.8 7.3 11.1
Distant recurrence 29.4 31.7 33.3
≥ 15% reduction of chemotherapy 8.8 21.9 22.5
* not all data available ** only extremity
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Treatment
Surgery
Concerning the surgical approach of osteosarcomas in extremities, no significant differ-
ence in 5-year DFS was seen between a limb-sparing resection and amputation (55.3% 
vs. 56.2%, p=0.921, Table IV). Amputation or rotationplasty were more often an option 
in patients ≤14 years than in the two other age groups (74.2% vs.39.4% and 34.6% 
respectively, Table II). The percentages of patients with marginal surgery margins were 
similar in the three age groups. 
Table IV. Treatment characteristics and DFS (N=102)
Variables  Number of patients
5-year DFS 
(%) p Value
a
Chemotherapy  
 CIS/DOXO/HD-MTX 20 63.2 -
 CIS/DOXO 70 40.0 0.138
 Adjuvant only 12 41.7 0.138
Histologic response*  
 Good 11 72.7 -
 Poor 70 45.7 0.169
Surgery*  
 Amputation 47 55.3 -
 Limb-salvage 48 56.2 0.921
Surgical margins*  
 Radical 10 60.0 -
 Wide 49 51.0 0.669
 Marginal 26 38.5 0.456
* not all data available
a  The significance level of Chi2 test
CIS=cisplatin, DOXO=doxorubicin, HD-MTX=high-dose methotrexate
Ado lescent  pat ients
The group of 41 adolescents (aged 15 to 19 years) included 21 patients treated in the 
pediatric department (mean age 15.9 years; range, 15.0 to 18.5 years) and 20 patients 
treated in the adult department (mean age 17.3 years; range, 15.2 to 18.7 years). The 
clinical characteristics of the patients did not differ between these two groups e.g. no more 
metastasis or difference in tumor mass was seen between these two groups (data not 
shown). No significant difference in outcome was seen between patients treated at the pe-
diatric department (OS 57.9% ±1.2%) and patients treated at the department of medical 
oncology (OS 47.4% ±1.2%, p=0.705, Figure I). 
Figure I. Overall survival in patients aged 15-19 years old
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Ana lys i s  o f  prognost i c  fac tors
Univar ia te  Ana lyses
On univariate analyses, older age, presence of metastases and tumors located in the axial 
skeleton were identified as predictors for worse overall survival (Table III). Patients ≤14 
years showed a significant better 5-year OS of 70.6% ±0.8%, compared to older patients 
aged 20 to 40 years old with an OS of 33.3% ±0.9% (p=0.002, Figure II). In univariate 
Cox regression, with age as an isolated, continuous variable, the risk ratio was 1.030 per 
increasing year (p=0.048; 95% CI: 1.000-1.061), indicating age is associated with surviv-
al to a significant degree. 
Figure II. Overall survival by age group
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We then analyzed whether the year of treatment affected the outcome due to differences 
in chemotherapy and surgical techniques over the past 30 years. The year of diagnose 
was analyzed as continue factor for a 5-year overall survival in a cox regression analy-
sis which showed no difference in survival according to the year of diagnosis (OR=0.99; 
95% CI: 0.96-1.03; p=0.96). Furthermore, we analyzed the age differences per protocol 
Chemotherapy
The 5-year DFS of the whole population was 47.1% ±1.6%. Patients ≤14 years showed a 
better 5-year DFS compared to their older counterparts (52.9% vs. 47.5% in patients 15-
19 years vs. 29.6% in patients >20 years, p=0.05).
Analyzing the different treatment regimens, the 5-year DFS of patients treated with cispla-
tin and doxorubicin (CIS/DOXO) was comparable in all age groups; 40.9% ±1.8% in pa-
tients ≤14 years (N=18) vs. 44.8% ±1.1% in patients aged 15-19 years (N=29) vs. 38.9 
% ±0.4% in patients aged >20 years (N=23). HD-MTX was not applied in patients older 
than 20 years of age because of increased toxicity of HD-MTX in elderly27; therefore, the 
influence of HD-MTX on the survival rate was studied in the pediatric population only. Pa-
tients younger ≤14 years (N=11) had a DFS of 72.7% ±0.5% vs. 50% ±0.9% in patients 
aged 15-19 years (N=9). Furthermore, patients ≤14 years had more often a good histolog-
ical response to chemotherapy than older patients (26.9% vs. 9.5%, p=0.058, Table II).
Treatment  ad jus tments
The cumulative dose of chemotherapy was reduced in 18 patients (17.6%). Reasons for 
reduction of chemotherapy were the following; two patients had antracycline-induced de-
creased left ventricular ejection fraction, four patients had ototoxicity (>20 dB loss at 4,000 
Hz), severe bone marrow suppression in 10 patients and in 2 patients chemotherapy was 
stopped for severe psychological problems. In 14/18 patients the cumulative dose of doxoru-
bicin was reduced with a median reduction of 30% (range 15-80%). Cisplatin was reduced in 
16/18 patients with a median reduction of 30% (range 15-50%) of the cumulative dose. The 
tendency to reduce dosage due to toxicity was higher in patients older than 14 years (Table 
II). Treatment adjustment was not associated with a reduced 5-years overall survival; 55.4% 
in patients without reduction vs. 44.4% in patients with reduction (p=0.51). Significantly 
less patients treated at the department of pediatrics received a dose reduction (4/55 pa-
tients, 7.2%) as compared to patients treated at the department of medical oncology (14/47 
patients, 29.7%, p=0.005). Also in the group of patients aged 15-19 years, dose reduction 
was more frequently applied at the department of medical oncology (4/20 patients) than at 
the department of pediatric oncology (1/21 patients). The presence of metastases at diag-
nosis was not a reason for dose reduction or dose intensification in the primary treatment. 
Recur rence  o f  the  d i sease
In total, 41 patients (40.2%) relapsed with a median of 15.3 months (range 2 to 101 
months) after finishing chemotherapy treatment. Of these 41 patients, nine developed 
local recurrence and 32 relapsed with distant metastases. Recurrence rates were similar in 
the three different age groups (Table II). At the last time point of follow-up (median follow 
up time 28 months after recurrence), nine of the relapsed patients were still alive. 
A: Age ≤ 14 years, N=34, OS 70.6% 
B: Age 15-19 years, N=41, OS 52.5% A vs. C p=0.002 
C: Age > 20 years, N=27, OS 33.3% B vs. C p=0.11
A vs. B p=0.11
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Discuss ion
In this retrospective, single center study we found that age above 20 years, presence of 
metastases and tumor location in the axial skeleton were significantly associated with 
decreased survival in patients with osteosarcoma. Presence of metastases at diagnosis 
and tumor location in the axial skeleton are generally accepted unfavorable prognostic 
factors13. Regarding age, however, results are contradictive. In line with our study are the 
results of Mankin et al.15 and Lee et al.16 studying 648 patients and 288 patients respec-
tively, both studies showing a worse outcome with increasing age. In contrast are the stud-
ies from the Rizzoli Institute showing an unfavorable prognosis for patients aged 14 and 
younger19,20,28. These differences in results might be explained by the fact that in the stud-
ies by the Rizzoli Institute no patients with metastasis were included as well as no patients 
with osteosarcoma in the axial skeleton. In our study however, all patients were included 
showing significant differences in exactly these two factors within the different age groups, 
namely less metastases at diagnosis and less tumors located in the axial skeleton in the 
younger age groups. This is in concordance to the literature where the general explanation 
for the poor prognosis in older patients includes increased axial distribution and metastatic 
disease at diagnosis27. Interestingly, regardless of these associations, we found that age 
remained a significant prognostic factor independent on metastatic stage at diagnosis and 
tumor location (p-value 0.004). 
Another recently published study by Hartig et al.29 showed that age as a continuous vari-
able was marginally prognostic significant. However, when patients were dichotomized by 
age, it was not found to be a significant prognostic variable. The chemotherapeutic proto-
cols used in the study of Hartig et al included the use of cisplatin and doxorubicin but no 
HD-MTX, one of the cornerstones in the treatment of pediatric patients with osteosarcoma. 
In our study, we showed in an univariate analysis that outcome was not dependent on the 
administered regimen. Patients older than 20 years of age, however, did not receive HD-
MTX, thus multivariate analysis correcting for age and the regimen used was not possible. 
It has been earlier suggested that especially patients younger than 12 years who received 
HD-MTX showed a substantially improved response and survival rate30. It is therefore pos-
sible that in the younger patients the addition of HD-MTX in the treatment of osteosar-
coma is beneficial and this explains the differences in survival. Addition of HD-MTX in the 
elderly patient, however, seems not the best option. In the study of Bacci et al.31, delayed 
clearance of HD-MTX resulting in severe toxicity was significantly correlated with the age 
of patients (6% for younger patients vs. 16% for patients older than 20 years: p=0.0001). 
For this reason HD-MTX is often not administered in patients older than 20 years as in our 
hospital which however, could play an important role in long-term survival. Although in the 
patients older than 20 years HD-MTX was not given in our study cohort, dose adjustment 
due to toxicity occurred more frequently than in patients younger than 20 years. Treatment 
adjustments were no predictor for inferior overall survival in the multivariate analysis. 
Adolescents with osteosarcoma may be treated at a pediatric department or at a medical 
and treatment period. This analyzes showed that independent on period of treatment and 
the different regimens that were used over the past 30 years, patients ≤14 years have a 
better survival compared to their older counterparts (Table V).
Table V. Overall survival according to period of treatment and treatment regimen
Treatment per periode
Age group 5-year OS-rate (%)
Treatment regimen
1979-1983  < 14 years 66.7%
adjuvant therapy 15-19 years   33%
 20-40 years    0%
1984-2002  < 14 years 57.1%
CIS/DOXO 15-19 years 39.3%
 20-40 years 18.2%
2003-2008  < 14 years   75%
CIS/DOXO/MTX in children 15-19 years 55.2%
CIS/DOXO in adults 20-40 years 42.9%
CIS=cisplatin, DOXO=doxorubicin, HD-MTX=high-dose methotrexate
Mul t ivar ia te  Ana lyses
A multivariate Cox proportional hazard analysis showed that age is an independent signif-
icant prognostic factor in relationship to OS after adjustment for other significant co-vari-
ables (Table VI). Patients ≥20 years of age were at greater risk of death than younger pa-
tients after adjustment for presence of metastases and tumor location in the axial skeleton 
(HR=3.2; 95% CI: 1.5-6.9; p=0.004). 
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oncology department. Several studies (predominantly in ALL) have indicated that out-
comes were better for adolescents treated at pediatric departments compared with pa-
tients treated at adult department18. To evaluate whether different treatment strategies of 
different departments (pediatric or adult department) is of influence regarding outcome 
in osteosarcoma patients, we investigated treatment results of the adolescence patients 
treated at our pediatric department (N=21) compared to adolescence patients at our adult 
department (N=20). Although the number of patients studied in the adolescence group is 
small, our results suggest that there is no difference in outcome regarding treatment at the 
adult oncology department versus pediatric oncology (58% vs. 47%, p=0.7).
The current study shows that patients younger than 14 years have a significantly better prognosis 
than patients older than 20 years. Although patients with osteosarcoma aged between 15-19 
years had an inferior survival compared to patients ≤14 years (52% vs. 70.6 %, respectively) 
this was not significantly different. These results however, show that there is a clear ten-
dency for decreased survival with increasing age. Different tumor biology in younger pa-
tients and/or different ability to cope with high-dose drugs compared to older patients 
might explain this difference, however, no data are yet available. With a better understand-
ing of the biology of osteosarcoma and more insight in age-related changes in the pharma-
cology of drugs (e.g. pharmacogenetics), better treatment regimens might be developed. 
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In t roduct ion
Osteosarcoma comprises 5% of all pediatric malignancies and is the most common pri-
mary bone cancer in children and adolescents. It is a highly aggressive tumor that usually 
involves the metaphysis of long bones and metastasizes primarily to the lung. Before the 
1970s, the prognosis for patients with high-grade osteosarcoma was poor, with long-term 
survival rates of less than 20%1. Advances in adjuvant and neoadjuvant chemotherapy 
have improved the 5-year disease-free survival (DFS) to more than 60%2. Since then 
different attempts have been made to further improve prognosis. However, it has been 
demonstrated that neither dose-intensification nor addition of newer agents does improve 
survi val3-6. Furthermore, patients that survive experience prolonged periods of rehabilita-
tion after long periods of chemotherapeutic treatment and after often disabling surgery. 
Although the long term toxicities have not been assessed completely, cardiotoxicity already 
emerged as a signifi cant price of cure for survivors of osteosarcoma patients7. Monitoring 
trends in survival and the long term toxicities is essential to enhance current treatment 
regimens. To gain more insight in the young patients, as osteosarcoma is predominantly 
being a disease that affects young patients, we investigate survival trends in this patient 
group and subsequently analyzed the occurrence of long term toxicity over the last three 
decades.
Mater ia l  and Methods 
Pat ients
In total 130 pediatric patients were consecutively treated between 1979 to 2008 in two dif-
ferent centers; Radboud University Nijmegen Medical Center and University Medical Center 
Groningen. All patients under the age of 20 years with newly diagnosed, primary localized 
or metastatic high-grade osteosarcoma were evaluated. Complete clinical and pathologic 
records, and appropriate data regarding follow-up were present. Informed consent was 
obtained for all patients. 
Treatment
Information from the patients’ medical charts about cumulative dosage of treatment, 
treatment response (good responders defined as <10% vital cells after neoadjuvant ther-
apy), reduction of chemotherapy (defined as >15% reduction of planned chemotherapy) 
and surgical approach were collected. The overall period was split into sub-periods relating 
to the major changes in protocol (1979-1983, 1984-2002 and 2003-2008). In the first era 
from 1979-1983 a T10-based multidrug regimen consisting of six cycles of doxorubicin 
30 mg/m2 daily for 2-3 consecutive days, six cycles of cisplatin 120 mg/m2 administered 
by repeated 6 hours infusions, 8-12 cycles of high-dose methotrexate (MTX) 8-12 mg/m2 
Abst rac t
Background
This study was conducted to investigate the clinical characteristics and treatment results 
of osteosarcoma in pediatric patients during the past 30 years. Trends in survival rates and 
long-term toxicity were analyzed.
Methods
In total, 130 pediatric patients under the age of 20 years with newly diagnosed, primary 
localized or metastatic high-grade osteosarcoma were analyzed regarding demographic, 
treatment-related variables, long-term toxicity and survival data. 
Resu l ts
Comparison of the different time periods of treatment showed that the 5-year OS im-
proved from 58.6% for children diagnosed during 1979-1983 to 78.6% for those diag-
nosed during 2003-2008 (p=0.13). Interestingly, the basic treatment agents includ-
ing cisplatin, doxorubicin and methotrexate remained the same. Treatment reduction 
due to acute toxicity was less frequent in patients treated in the last era (7.1% vs. 
24.1% in patients treated in 1979-1983; p=0.04). Furthermore, late cardiac effects 
and secondary malignancies can become evident many years after treatment and can have 
profound impact on cancer survivors.
Conc lus ion
We elucidate the prevalence of toxicity to therapy of patients with osteo sarcoma over the 
past 30 years. The overall improvement in survival may in part be attributed to improved 
supportive care allowing regimens to be administered to best advantage with higher toler-
ance of chemotherapy and therefore less chemotherapy related toxicity.
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Resu l ts  and D iscuss ion
Pat ients 
The median age at diagnosis was 14.4 years (range 4.5 to 19.9 years). There were 72 
male patients (55.4%; median age 14.8 years; range, 6.3 to 19.9 years) and 58 female 
patients (44.6%; median age 13.9 years; range, 4.5 to 19.1 years). At diagnosis, 29 pa-
tients (22.3%) had metastases and in 9 patients (6.6%) the tumor was located in the axial 
skeleton. 
Surv iva l
Overa l l  surv iva l
At a follow-up ranging between 4 and 33 years (median 8.9 years), 51 patients (39%) died. 
Of all deaths, 45 were directly related to osteosarcoma with 16 deaths due to progressive 
disease, 8 due to local recurrence and 21 after the development of distant metastases. 
The development of recurrent disease was predictive of death. Incidence of recurrences 
was relatively stable after 5 years with only 3 patients developing disease recurrence more 
than 5 years after diagnosis. Of the remaining 6 patients that died, 4 patients developed a 
SMN which was fatal, and 2 patients passed away due to antracyclin-induced cardiomyop-
athy. The 5-year OS of the whole population was 66.9% ±0.15, the 10-year OS was 64.6% 
±0.23 and the 20-year OS was 62.3% ±0.82. These findings are in concordance with ear-
lier reports in the literature12,13. In total, 60 patients had a follow-up longer than 5 years, 
38 patients were followed for more than 10 years and a group of 20 patients was followed 
beyond 20 years. Comparison of the different time periods of treatment showed that the 
5-year OS improved from 58.6% for children diagnosed during 1979-1983 to 78.6% for 
those diagnosed during 2003-2008 (p=0.13; Figure I). The distribution of known prog-
nostic factors, such as metastatic disease at diagnosis, tumor location and good histologic 
response to neoadjuvant chemotherapy was comparable regarding the different time pe-
riods (Table I). 
with appropriate folinic acid rescue and 1-2 cycles of Bleomycine, Cyclophosphamide and 
D-Actinomycine (BCD) was used. From 1984-2002 trials with control arm treatment of six 
cycles of doxorubicin 25 mg/m2 daily for 3 days in combination with cisplatin 100 mg/m2 as 
a continuous infusion were used. The comparison arm consisted of only four doxorubicin/
cisplatin courses and additionally 4 courses high dose MTX 4 mg/m2 with appropriate folinic 
acid rescue. The last era from 2003-2008 patients were treated with six cycles of doxorubi-
cine 25 mg/m2 daily for 3 days, four cycles of cisplatin 120 mg/m2 as a continuous infusion 
and 12 cycles of high-dose MTX 8-12 g/m2 with appropriate folinic acid rescue. 
Surv iva l
Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Mei-
er method8. OS was defined as the interval between diagnosis and death from any cause. 
Patients alive at the date of last follow-up were censored at that time point. DFS was 
defined as the interval between diagnosis and disease progression/recurrence. Patients 
without disease recurrence at the date of last follow-up were censored at that date. Cox’s 
proportional hazard regression analysis was used to determine significance of differences 
in survival curves. Confidence intervals were calculated at the 95% level. We evaluated 
gender, location, stage, treatment, treatment response, toxicity-induced reduction of che-
motherapy as prognostic factors. Associations between outcome and potential predictors 
were evaluated with the Fisher’s exact test for categorical variables. Statistical analysis 
was performed using SSPS software (version 16.0, SSPS Inc, Chicago, IL). 
Long term tox ic i t i es
Long term toxicities after chemotherapeutic treatment was evaluated regarding develop-
ment of secondary malignancies, cardiotoxicity and ototoxicity. The length of time at risk 
for the secondary malignancy neoplasm (SMN) was calculated from the date of diagnosis 
of primary osteosarcoma until the date of diagnosis of the second malignancy. The cumu-
lative incidence rate of SMN was calculated based on the method of Gray9. For the analysis 
of cardiac toxicity resulting from doxorubicin therapy, we included surviving patients who 
underwent serial echocardiographic evaluations before, during and at least one follow-up 
echocardiogram after the initial treatment with doxorubicin. An echocardiogram at the end 
of chemotherapy was recommended annually for 5 years. Data concerning the fractional 
shortening (FS) value were collected. Cardiac dysfunction was defined as a decrease in FS 
<28% or a reduction of more than 10%10. Hearing loss, a complication of cisplatin was defined 
 according to Brock Criteria11 (grade 0: <40 dB at all frequencies; grade1: ≥40 dB at 8000 
Hz; grade 2: ≥40 dB at 4000 Hz; grade3: ≥40 dB at 2000 Hz; grade 4: ≥40 dB at 1000 
Hz). For this analysis only survivors were included with a baseline audiogram and an au-
diogram at the end of treatment.
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Disease  f ree  surv iva l
The 5-year DFS of the whole group was 59.2% ±0.18. Patients with non-metastatic osteo-
sarcoma disease showed a DFS of 65.3% vs. 37.9% in patients with metastases at diagno-
sis. During the past 3 decades the DFS of patients with metastases increased from 28.6% 
in 1979-1983, 40.0% in 1984-2002 to 42.9% in 2003-2008. The same trend is seen in 
patients with bad histologic response to neoadjuvant chemotherapy: 5-year DFS increased 
from 30% in 1979-1983, 57.6% in 1984-2002 to 65.4% in 2003-2008. Comparison of DFS 
in patients with axial involvement was not possible due to a small group. 
Treatment
Chemotherapeut i c  t reatment
In the first era, surgical resection was performed after 4 weeks of neoadjuvant chemother-
apy, after 1984 resection was performed in the 10th week of induction therapy. Good his-
tologic response to neoadjuvant chemotherapy was observed in 13.3% of patients treated 
with cisplatin and doxorubicin and in 29.4% of patients additionally treated with MTX 
(p=0.083). Although, an increased rate of good histologic responders was seen in the 
group additionally treated with MTX, comparing the regimen arms with and without MTX 
no evident difference was seen in 5-year OS (HR=0.75, 95% CI=0.39-1.27; p=0.24) or 
5-year DFS (HR=0.75, 95% CI=0.43-1.29; p=0.29). The effect of high-dose MTX in the 
treatment of osteosarcoma is not unambiguously proven in the literature. Several studies 
have shown a relationship between peak serum concentrations of MTX and improved histo-
logic response14-16. However, a Cochrane systematic review comparing the effectiveness of 
MTX was unable to make clear conclusions due to the lack of randomized controlled trials 
using high-dose MTX as the only difference between the intervention and control group17.
Tox ic i ty  re la ted  t reatment  reduct ion
Chemotherapy was reduced due to severe bone marrow depression (N=6), renal toxicity 
(N=3), ototoxicity (N=3), cardiotoxicity (N=3) and adverse effects to MTX, like MTX en-
cephalopathy (N=1) or allergic reactions to MTX (N=3). Interestingly, treatment reduction 
due to acute toxicity is less frequent in patients treated between 2003-2008 than in pa-
tients treated between 1984-1998 and in patients treated between 1979-1983 (p=0.04, 
Table I). 
Figure I. 5-year overall survival in Pediatric patients with osteosarcoma over three decades
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Table I. Distribution of prognostic factors over three decades
Prognostic factor (N) 1979-1983 1984-2002 2003-2008 P
 N=29 N=59 N=42  
Metastases at diagnosis 24.1% (7) 25.4% (15) 16.7% (7) 0.58
Tumor in axial skeleton 6.9% (2) 8.5% (5) 4.8% (2) 0.51
Good histologic response 24.1% (7) 23.7% (14) 35.7% (15) 0.55
> 15% reduction due to toxicity 24.1% (7) 20.3% (12) 7.1% (3) 0.04
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Card io tox ic i ty
In 46 patients sufficient data concerning baseline and follow-up echocardiogram was avail-
able. No patient had clinically evident cardiac disease before chemotherapy. Before starting 
therapy with doxorubicin the median FS value was 36%. In 8 patients the FS decreased 
<28% during therapy, with a median change in the percent FS value of 4% which is in 
concordance with earlier studies on this subject21. The long-term implications of doxorubi-
cin-associated echocardiographic abnormalities are not fully understood, but at least one 
study suggests that echocardiographic abnormalities are progressive over time22. In our 
cohort, 3 patients with decreased FS during therapy remained to have cardiac dysfunction 
after finishing primary treatment. In total, 11 out of 46 patients developed cardiac dys-
function in the follow-up period. The median frequency of cardiac evaluation in the first five 
years was three (range 1 to 5 evaluations). The median latency of cardiac effects after fin-
ishing primary therapy was 219 days (range 30 days to 28.2 years). Six out of 11 patients 
with cardiac dysfunction experienced symptomatic heart failures; 4 of them more than 5 
years after primary treatment and regular controls. Two patients died of cardiomyopathy 
and 3 of metastatic disease, which occurred after the diagnosis of cardiomyopathy. Affect-
ed patients were predominantly treated in the first two decades of our study realizing that 
the last cohort treated might not had enough follow-up to adequately evaluate this late 
squeal. All patients received a mean cumulative doxorubicin dose of 450 mg/m2. 
Ototox ic i ty
Cisplatin associated hearing loss develops in the period cisplatin is administered and it 
has already been observed in patients treated with a single dose of 50 mg/m2 23. However, 
it is unlikely to improve over time and as even mild hearing loss can have considerably 
impact on the social-emotional development of a child24 it is considered to be one of the 
late effects in the treatment of osteosarcoma patients. Of the 79 survivors in our study, 62 
(78.5%) had an audiogram at the end of treatment. Pre-existing hearing loss was not re-
ported in one of these patients. Of the 62 survivors with an audiogram, 31 patients (50%) 
had no hearing loss, 23 patients (37.1%) were Brock grade I and 7 patients (11.1%) de-
veloped severe hearing loss (Brock grade 3 and 4). All patients with severe hearing loss 
required hearing aids. No difference was seen in cumulative dosage of cisplatin comparing 
patients with severe hearing loss (cumulative dosage: 407 mg/m2) versus patients with 
grade 0, 1 or 2 hearing loss (cumulative dosage: 442 mg/m2, p=0.55). Furthermore, no 
difference in prevalence of severe ototoxicity was seen between the drug regimens using 
either 600 mg/m2 or 480 mg/m2 cisplatin (p=0.25) or continuous infusion versus repeated 
6 hours infusions (p=0.76).
Surg ica l  t reatment
Analysis of surgical treatment method showed a rise from 26.9% of patients with limb 
salvage treatment in 1979-1983 to 69% in 2003-2008. The 5-year DFS rates were 57.8% 
for limb salvage treatment and 66.1% for amputation (HR=1.35, 95% CI=0.76-2.39, 
p=0.30). The advancement of patients with limb salvage treatment could be expected 
considering that amputation patients might have had more advanced disease. A slightly 
but not significant improvement of DFS was seen in both surgical methods over the past 
three decades (data not shown).
Long term tox ic i ty
Secondary  mal ignancy  neop lasm
In total, seven patients (5.3%) developed a second malignancy, with a median latency 
from original diagnosis to second malignancy of 12 years (range 2.4 to 23 years). Second 
malignancies were 2 patients with acute lymphatic leukemia, 4 patients with breast can-
cer and one patient with gastric adenocarcinoma. Of the 7 patients who developed SMN, 
2 patients had a history of Li-Fraumeni syndrome. Both patients developed SMN within 
5 years after treatment of osteosarcoma. The 5- and 10-year estimated cumulative SMN 
incidence rates were 1.5% ±1.1% and 3.1% ±1.3%, respectively, which is similar to 
earlier studies in survivors of osteosarcoma18,19. Overall, the incidence ratio of secondary 
malignancies in long term survivors of osteosarcoma is much less compared to other ma-
lignancies, e.g. Hodgkin disease20. However, the cohort has been followed for a median of 
8.9 years, and it is likely that with increasing follow-up, SMN will emerge, due to a latency 
of 10 to 15 years. 
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Like other studies in childhood cancer25 we showed an improved survival of patients with os-
teosarcoma over the past decades. This improvement is seen in all subgroups irrespective 
of known prognostic factors like metastases at diagnosis or histological response to neoad-
juvant therapy. This increase in childhood cancer survival is often attributed to more effec-
tive treatment strategies. However, in our study the treatment agents and dosage basically 
remained the same over the past 30 years with cumulative doses of doxorubicin 450 mg/m2, 
cislpatin 480 or 600 mg/m2 and high-dose MTX 96-144 g/m2 appropriate to age. Furthermore, 
there was no difference in method of administration regarding doxorubicin and high-dose 
MTX. Cisplatin was administered as a 6 hours infusion during 1979-1983 in our study and 
then as continuous infusion. While continuous cisplatin infusions are observed to be consid-
erable ototoxic26, we found no difference in our study. Generally, other factors like empiric 
use of broad spectrum antibiotics in case of neutropenic fever, pain management, anti-
emetics, nutrition, blood banking and improved pediatric intensive care might have im-
proved the acceptability of the current treatment. On the other hand, with an increasing 
number of cancer survivors detection of late effects of osteosarcoma therapy is required. 
In this study we show that late cardiac effects and SMN can become evident many years 
after treatment and can have profound impact on cancer survivors. 
In conclusion, these data elucidate the prevalence of toxicity to therapy in children with 
osteosarcoma. Further studies concerning the management of long-term toxicities are 
needed to finally improve survival rates in patients with osteosarcoma. 
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In t roduct ion
Osteosarcoma is the most frequent primary malignant tumor of the bone. With current 
treatment regimens, the 10-year overall survival approaches 60%1. Major progress in the 
therapy of patients with osteosarcoma was achieved in the early 1970s when chemother-
apy was added to surgery2,3. However, survival rates have reached a plateau over the last 
decade, suggesting that we have reached the limits of currently applied therapy modalities. 
Further improvement in outcome and reduction in toxicity will require the identification and 
application of new prognostic factors and novel treatment strategies. 
Multiple studies have suggested that outcome in different types of cancers may be affected 
by how rapidly and effectively an individual patient metabolizes certain chemotherapeutic 
agents4. Genetic variations can affect the effectiveness and toxicity of chemotherapeutic 
agents5. Germ line DNA is needed to identify the genetic factors underlying toxicity and 
efficacy of drugs that are currently used in the treatment of cancer. However, most clini-
cal trials performed so far in cancer treatment did not routinely collect and store patient 
germ line DNA. Formalin-fixed paraffin-embedded tissues (FFPE) from archived clinical 
samples could provide a source of germ line DNA for genetic research. Specially, in cancers 
like osteosarcoma with a 5-year overall survival (OS) of approximately 50-60%, archived 
histological specimens are often the only accessible source of biological material. How-
ever, DNA obtained from such samples may be different from the original germ line DNA 
extracted from white blood cells (WBCs) or buccal swabs due to several reasons: The DNA 
from FFPE tissues has a higher frequency of non-reproducible sequence alterations com-
pared with germ line DNA6. It has been hypothesized that the artifacts are caused due to 
formalin fixation as this can lead to cross-linking between cytosine nucleotides on either 
strand of the DNA as well as to cross-linking between histone proteins that normally coat 
the DNA. In both cases DNA amplification in a polymerase chain reaction (PCR) can be 
unreliable. First, cross-linking of cytosine nucleotides precludes the Taq DNA to recognize 
the cytosine which therefore, incorporates an adenine instead of a guanine resulting in an 
artificial C-T or G-A mutation7,8. And second, cross-linking of histone proteins is likely to 
affect accessibility of the DNA by Taq DNA polymerase and the subsequent progression of 
the polymerase along native DNA template making the DNA inaccessible to PCR9. Further-
more, fixed bone tumor often requires acid decalcification prior to processing, which may 
cause additional DNA fragmention that potentially influences the result of subsequent SNP 
analysis10,11. Especially, when assays are based on relatively long amplicons (above ~200 
base paires), fragmentation of DNA influences the reliability of the evaluation. 
Although, previous studies have used FFPE material for molecular diagnostics in patients 
with osteosarcoma12-14, only one report has used decalcified FFPE material for DNA isola-
tion. In this report DNA from decalcified FFPE samples was unsuitable for genotype anal-
ysis due to significant degradation of DNA based on decalcification15. Consequently, there 
are no studies reporting the successful experience of extracting DNA from decalcified FFPE 
Abs t rac t
Background 
In cancers like osteosarcoma with a 5-year overall survival of 50-60%, archived histologi-
cal specimens can be a useful source of biological material. However, this material gener-
ally has been decalcified and formalin-fixed for many years. In our study, we investigated 
whether DNA obtained from these tissues can be used for reliable single nucleotide poly-
morphism (SNP) genotyping. 
Methods 
We studied two SNPs in the drug transporter MDR1 using Taqman® SNP genotyping assays. 
Genotypes of the germ-line DNA derived from freshly isolated DNA of 20 surviving patients 
with osteosarcoma were compared with genotypes obtained from archived material from 
decalcified formalin-fixed, paraffin-embedded (FFPE) blocks of the same patients. 
Resu l ts 
Decalcified FFPE-derived DNA yielded smaller polymerase chain reaction (PCR) fragments 
compared to DNA extracted from peripheral blood cells, with a reliable size of ~200 bp. 
However, we were able to evaluate each SNP in 19 of 20 cases included in this study. All 
successfully genotyped samples showed 100% concordance between genotypes obtained 
from DNA of FFPE tissue and the genotypes obtained from DNA of blood from the same 
patients. 
Conc lus ions 
In conclusion, we have demonstrated that decalcified FFPE tissue can be used for genetic 
polymorphism analysis using Taqman® allelic discrimination assays. This forms an unique 
opportunity to combine new insights in genetic research with historical patient cohorts.
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TRIS buffer (NaCl [5M], Tween-20[20%], Ethanol[70%]) for 15 minutes at 90 ºC. After 
centrifugation (14,000 rpm) 20 µl Proteinase K solution was added to the pellet. Samples 
were incubated for 3 days in a heating block (first day at 56 ºC, second and third day at 
37 ºC); every day 20 µl Proteinase K solution was added to the samples. After the incu-
bation period, samples were centrifuged at 14,000 rpm for 10 min, the supernatant was 
removed. This step was repeated twice. Then, 4 µl RNase (100 mg/ml) solution was added 
and the DNA was isolated using the DNeasy Tissue kit as described by the manufacturer 
(Qiagen Inc., Valencia, CA. USA) with the modification that 20 µl AE buffer was applied 
twice instead of once.
DNA qua l i ty  cont ro l
The nucleic acid purity was determined by a 260/280 nm and 230/280 nm optical density 
(OD) measurement using the NanoDrop (Thermo Scientific NanoDrop™ 1000 Spectropho-
tometer). A qualitative size range PCR assay was performed to determine DNA quality of 
the normal FFPE tissue. The assay consists of 5 primer sets, that amplify products ranging 
from 100 bp to 400 bp (Table I) and has successfully been used before16.
Table I. Primer sequences for the gel electrophoresis assays
Position NCBI Forward/Reverse primer Primer sequence 5’-3’
TBXAS1/X9U (388) Forward primer GCC CGA CAT TCT GCA AGT CC
TBXAS1/X9L (487) Reverse primer GGT GTT GCC GGG AAG GGT T
RAG1/X2U (610) Forward primer TGT TGA CTC GAT CCA CCC CA
RAG1/X2L (809) Reverse primer TGA GCT GCA AGT TTG GCT GAA
PLZF/X1U (11587) Forward primer TGC GAT GTG GTC ATC ATG GTG
PLZF/X1L (11886) Reverse primer CGT GTC ATT GTC GTC TGA GGC
AF4/X11U (486) Forward primer CCG CAG CAA GCA ACG AAC C
AF4/X11L (885) Reverse primer GCT TTC CTC TGG CGG CTC C
AF4/X3U (218) Forward primer GGA GCA GCA TTC CAT CCA GC
AF4/X3L (817) Reverse primer CAT CCA TGG GCC GGA CAT AA
Matching DNA from normal cells was used as a control. Genomic DNA (50 ng) was ampli-
fied using dNTPs (2 mM), PCR-buffer II, MgCl2 (25 mM), 10 pmol of each primer, and Taq 
polymerase (2.5 U). PCR conditions were 94 °C for 10 minutes followed by 35 cycles of 
92 °C for 30 seconds, 60 °C for 40 seconds and 72 °C for 40 seconds. MilliQ was includ-
ed as negative controls in all PCR experiments. PCR products were visualized using 2% 
ethidium bromide-stained agarose gels. The bands were visualized and recorded using the 
Imago (Isogen Bioscience, IJsselstein, The Netherlands). Absence of DNA bands indicat-
tissue. Therefore, we analyzed whether the genotypes obtained from DNA of these tissues, 
were comparable with the genotypes obtained from freshly isolated DNA from saliva or 
peripheral blood cells from the same patients. 
Mater ia l s  and methods
Pat ients  and samples
We included samples of 20 patients with primary, high-grade osteosarcoma. From each 
patient, germ line DNA was isolated from blood or saliva and from stored normal FFPE 
tissue. Collection and extraction of germ line DNA from blood or saliva samples occurred 
in 2008 and 2009. All these patients had an excision of the tumor between 1997 and 
2008. At time of surgical resection, fresh tissue material was fixed in 4% formaldehyde, 
phosphate-buffered at pH 7.0 (Klinipath, Duiven, The Netherlands) for 12 to 16 hours at 
room temperature. Ten of the 20 tissue samples were decalcified in 10% formic acid for 
approximately one week. The tissue material was then dehydrated in a Schandon Excelsi-
orTM ES Tissue Processor (Thermo Fisher Scientific Inc., Breda, The Netherlands) according 
to the following procedure: 5.5 hours, 50% alcohol; 4 hours, 70% alcohol; 6.5 hours, 96% 
alcohol; 7.5 hours, 100% alcohol; 2 times 1 hour, 100% alcohol; 3 times 1.5 hours, xy-
lene; 3 times 1.5 hours, paraffin; and finally embedded in paraffin. The tissue blocks were 
stored at room temperature. At time of DNA extraction from the FFPE blocks, the sam-
ples had been embedded in paraffin blocks for 1-11 years. From the FFPE blocks we used 
muscle samples (N=15) or other tissues (N=5) such as skin or lymph nodes as normal 
tissue source. Sample size was uniform, 1.5 cm x 2.5 cm. All samples were assessed by 
an experienced pathologist on hematoxylin/eosin stained slides before samples were used 
for DNA extraction. In 3 patients, the FFPE blocks contained normal (non-tumor) tissue 
as well as tumor tissue. In these cases, regions containing tumor cells were indicated by 
an experienced pathologist and removed by macro-dissection after which non-tumor germ 
line DNA was isolated. 
DNA ext rac t ion  f rom b lood and sa l iva
DNA of EDTA whole blood (5 x 106 WBCs) was extracted using the QIAamp DNA Blood Midi 
kit (Qiagen Inc., Valencia, CA. USA), according to the manufacturers protocol. DNA of sali-
va (2 ml) was collected in the Oragene saliva collection kit (DNA Genotek, Kanata, Ontario, 
Canada) using the Oragene DNA purification protocol as supplied by the manufacturer. 
DNA ext rac t ion  f rom FFPE t i ssue
Paraffin embedded samples were sectioned using standard microtome techniques. Four 
tissue sections of 10 µm were placed in 1.5 ml tubes. The microtome was carefully cleaned 
with ethanol between cases to avoid contamination. Samples were incubated in 200 µl 
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Resu l ts
Twenty patients with osteosarcoma were included in the study. Germ line DNA, both from 
blood/saliva and from FFPE material was collected of all patients. The median DNA yields 
of the different sources are shown in Table III. 
Table III. DNA yields
Type of sample N (samples)
DNA yield (µg) 
median (range)
Blood (WBCs 5 x 106) 14 30.0 (6.6-82.0)
Saliva (2 ml) 6 55.1 (8.9-134.0)
Decalcified FFPE (4 x 10 µm-slided, 1.5 à 2.5 cm) 10 9.1 (0.65-19.2)
Non-decalcified FFPE (4 x 10 µm-slided, 1.5 à 2.5 cm) 10 9.8 (0.67-24.3)
The median yield for embedded tissues (4 x 10 µm-slices of 1.5 x 2.5 cm) was 9.4 µg, 
ranging from 0.65 µg to 24.3 µg. The quality of the DNA derived from decalcified FFPE 
samples was comparable to the quality of the non-decalcified FFPE samples. The mean OD 
260/280 ratio of non-decalcified FFPE tissue was 1.80 (range 1.39-1.91) and the mean OD 
260/280 ratio of decalcified FFPE tissue was 1.77 (range 1.0-2.70). 
We performed a size range PCR to determine if decalcification results in DNA degradation. 
Figure I shows the results of the PCR of eight samples of germ line DNA from blood/sali-
va compared to germ line DNA derived from FFPE tissue of the same patients. Analyses 
by gel electrophoresis revealed that the PCR reactions worked efficiently with DNA from 
blood/saliva. For DNA extracted from FFPE samples, PCR became increasingly inefficient 
the longer the amplicons were. In three of the four sets of decalcified FFPE samples, the 
electrophoresis gel showed amplicon sizes from 100 bp to 300 bp. Bands were absent in 
one of the decalcified FFPE samples. The other four sets with non-decalcified normal FFPE 
tissue showed an amplicon size from 100 bp to 300 bp. However, the 300 bp fragments 
were less intense compared to germ line DNA derived from blood/saliva, indicating some 
degree of DNA degradation in the FFPE samples.
ed degradation of the DNA. The degree of DNA degradation is related to the number of 
non-amplified bands, the largest products will disappear first.
Genotyping by TaqMan® Allelic Discrimination
Two SNPs in the drug transporter MDR1 (ABCB1), rs1045642 and rs2032582 were geno-
typed using Taqman® allelic discrimination assays (Table II, Applied Biosystems, Nieuw-
erkerk aan den IJssel, The Netherlands). Amplicon size ranges between 70-90 bp. The SNP 
rs2032582 is tri-allelic, meaning that three different nucleotides can occur at the same 
genomic location. Two assays were used to detect all three nucleotides of this SNP.
Table II. Genotyping results
success rate (N)
Gene SNP Assay Name
blood/
saliva
non-
decalcified 
FFPE
decalcified 
FFPE
ABCB1 rs1045642: C>T C_7586657_20 20/20 10/10 9/10
 rs2032582: C>A C_11711720C_30 20/20 10/10 10/10
 rs2032582: C>T C_11711720C_40 20/20 9/10 10/10
The PCR reactions were performed according to the manufacturer’s protocol using 10 ng 
DNA in a final volume of 10 µl. The PCR amplification was performed using the following 
conditions: 12 min at 95 °C, 50 cycles of 15 sec at 92 °C and 90 sec at 60 °C. The fluores-
cent signal for allelic discrimination was determined after amplification using an end-point 
reading on the 7500 Fast Real-time System (Applied Biosystems). Automated allele calling 
was performed by allelic discrimination plots using SDS 1.4 software (Applied Biossys-
tems). We included 5% duplicate samples in each plate as quality control. 
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Discuss ion
Genetic studies are necessary to get a better understanding of tumor biology and the treat-
ment response in malignancy. However, in patients with osteosarcoma, in which survival 
rates are about 60%, representative material for genetic studies often is only present in 
the form of decalcified, formalin fixed specimens. So far, successful application of genetic 
studies on decalcified, FFPE tissues have not been reported. Reliable results with quantita-
tive PCR have only been shown on tissue that has not been decalcified. 
In a few reports, decalcified FFPE material has been used for DNA or RNA isolation. In one 
report DNA from decalcified FFPE tissues was unsuitable for genotype analysis due to sig-
nificant degradation of DNA based on decalcification15. In two other reports, RNA extracted 
from decalcified samples was of poor quality and reliable for real-time PCR in only 5/35 and 
6/40 of the cases, respectively17,18.
In the present study, we demonstrate that long-term stored, decalcified FFPE tissues, can 
be reliably used for Taqman® genotyping assays. We were able to evaluate each SNP in 19 
of the 20 cases included in this study. All successfully genotyped samples showed 100% 
concordance between genotypes obtained from DNA of decalcified FFPE tissue and the 
genotypes obtained from DNA of blood/saliva. No misclassifications were seen. 
Decalcification of tissues is often necessary to soften the bone in order to achieve accept-
able 3-6 µm sections of bone for histological studies. This process is carried out by remov-
ing the mineral with acids which leads to additional fragmentation of the DNA, making the 
recovery of nucleic acids even more challenging. In our study, we optimized our protocol 
with a prolonged incubation time of proteinase K. The most important role of protease 
digestion is to destruct the cells, but also to de-cross link histone proteins from native 
DNA, which has occurred to formalin fixation19. Using this modified protocol, we were able 
to obtain adequate DNA in decalcified FFPE tissue suggesting that with this simple adap-
tation, DNA can be successfully recovered from decalcified archived tissue. Furthermore, 
the ability to amplify PCR products of 200 bp suggests that decalcified FFPE samples might 
as well be used on other genotyping methods, like high throughput genotyping using the 
Illumina system20,21.
In conclusion, we have demonstrated that formalin fixed and paraffin embedded tissue, 
whether decalcified or not, can be used for genetic polymorphism analysis using Taqman® 
allelic discrimination assays. This forms an unique opportunity to combine new insights in 
genetic research with historical patient cohorts, for instance in patients with osteosarcoma. 
Figure I. Results of the size-range PCR to assess the integrity of DNA from decalcified FFPE tissue
 M 1a 1b 2a 2b 3a 3b 4a 4b M 5a 5b 6a 6b 7a 7b 8a 8b M
M: 100 bp size ladder 
a: DNA isolated from blood or saliva, b: DNA isolated from matching FFPE tissue
Lanes 1-4: DNA isolated from decalcified normal FFPE tissue; 
Lanes 5-8: DNA isolated from non-decalcified normal FFPE tissue
Genotyping of two SNPs (3 genotype assays) in the ABCB1 gene was performed on all 
samples. Genotyping was successful in all blood/saliva samples (N=20) for each assay. 
For one of the 10 decalcified FFPE samples, we were unable to genotype rs2032582 C>T 
(Table II, sample 4b). For non-decalcified samples (N=10), genotyping of SNP rs1045642 
failed for one sample (not shown as DNA yield was too low for size range PCR). In the 18 
patients in which both DNA from FFPE and blood/saliva was available, a 100% concordance 
was seen comparing the genotypes obtained from DNA of the FFPE tissues to those of 
freshly isolated DNA from saliva or peripheral blood cells from the same patients. The two 
samples with unsuccessful genotyping were re-analyzed to exclude technical problems; in 
addition a random selection of 10% of all samples was genotyped twice as quality control. 
All samples replicated showed consistent genotypes.
400 bp
300 bp
200 bp
100 bp
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In t roduct ion
High dose methotrexate (MTX; 1 g/m2-8 g/m2) is widely used in the treatment of childhood 
cancer, including acute lymphoblastic leukemia (ALL) and osteosarcoma. Previous studies 
have shown that a systemic exposure to higher concentrations of MTX, including standard 
leucovorin rescue, is associated with an increased response to chemotherapy1-4. On the 
other hand, plasma concentrations greater than 1 µmol/l at 48 hours after MTX treatment 
are associated with increased risk of side effects5,6. Monitoring of MTX plasma levels allows 
early detection of a delayed elimination. Prolonged leucovorin rescue and/or hydration are 
administrated to prevent MTX toxicity when plasma levels at 48 hours after infusion are 
not <0.4 µmol/l. This strategy has significantly reduced the frequency of serious adverse 
effects and MTX-induced toxic deaths. However, prolonged leucovorin rescue should not 
be given too excessively as there may be a risk of potentially over-rescue these patients 
and annihilate the desired antitumor effect of MTX. For appropriate use of MTX it would 
therefore be useful to identify factors that affect MTX elimination and the risk of MTX-relat-
ed adverse effects. Identifying patients with an a priori risk for high or low MTX clearance 
could be clinically useful to individualize MTX dosage and avoid toxic MTX exposure. 
MTX is predominantly metabolized by the folate pathway. Studies in rheumatoid arthritis, 
where low-dose MTX is used as treatment, have suggested that polymorphisms in genes 
involved in the folate pathway may indeed influence the pharmacokinetics of MTX7-9. Until 
2010 only a few predominantly single gene studies in ALL and no study in patients with 
osteosarcoma have been published regarding the role of pharmacogenetics on MTX plasma 
concentration. Genes studied were GGH10, ABCC211 and MTHFR12,13. These studies indicate 
that variants in the folate pathway may explain interpatient variability in MTX plasma levels 
and/or MTX related toxicity. Here, we are the first to study candidate genes known to be 
involved in the MTX processing pathway regarding their influence on MTX levels at 48 hours 
after infusion and toxicity in ALL and osteosarcoma patients. 
Abs t rac t
Background
High-dose methotrexate (MTX) forms a cornerstone in the treatment of several pediatric 
malignancies including acute lymphoblastic leukemia (ALL) and osteosarcoma. Delayed 
MTX elimination necessitates increased leucovorin rescue which may potentially annihilate 
the desired antitumor effect. We investigated if genetic variations in genes coding for en-
zymes in the MTX processing pathway are associated with delayed MTX elimination.
Methods
In total 92 children with ALL (N=49) and osteosarcoma (N=43) were genotyped for 40 
functional genetic variants in 20 genes in the MTX processing pathway. MTX plasma con-
centrations at 48 hours following the start of each MTX course and MTX-induced toxicity 
(grades 0-4 according to the CTCAE criteria) were assessed. Differences in MTX levels 
between genotype groups were tested using generalized estimated equations (GEE) with 
robust standard errors to take repeated measurements into account. Analyses were per-
formed under the assumption of an additive model. 
Resu l ts
In total, 640 courses of high-dose MTX were evaluated. At least one episode of MTX-in-
duced toxicity grade 3 or 4 was recorded in 41.8% of the patients. Four polymorphisms 
showed an association with MTX plasma levels with p-value <0.10: ABCC2 c.3972C>T, 
AMPD1 c.34C>T, ITPA c.94C>T, GSTT1del. Association analyses for the four polymor-
phisms for MTX-induced toxicity (grade 3 and 4) showed however no statistically significant 
association.
Conc lus ion 
This study identified four polymorphisms associated with elevated MTX plasma levels. Lim-
ited by small sample size and the retrospective nature of the study, the observed associa-
tions deserve further validation.
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Selection of polymorphisms and genotyping
Genomic DNA was isolated from blood using the QIAamp DNA Blood Midi kit (Qiagen, 
Venlo, The Netherlands) or saliva collected with the Oragene saliva collection kit (DNA Ge-
notek, Kanata, ON, Canada) according to the manufacturer’s protocols. 
NCBI databases (PubMed, Gene) and the Pharmacogenomics Knowledge Base (www.
pharmgkb.org) were searched for candidate genes known to be involved in the MTX pro-
cessing pathway. In total, 15 of the most important genes reported to play a role in the 
folate cycle (TYMS, DHFR, CBS, MTHFR, SHMT, MTR, MTRR, MTHFD1, ATIC, AMPD1, GGH, 
GST, FOLH1, ITPA and FPGS) were selected. Additionally, 5 genes coding for MTX trans-
porters (ABCB1, ABCC1, ABCC2, ABCG2, SLC19A1) were studied. In these 20 genes, poly-
morphisms that have been previously reported to be associated with MTX-pharmacoki-
netics and toxicity were selected for analysis. In total, 40 polymorphisms (Supplementary 
Table 1) were genotyped using Taqman allelic discrimination assays according to the pro-
tocol of the manufacturer (Invitrogen, Bleiswijk, The Netherlands). After amplification, the 
fluorescent signal for allelic discrimination was determined using the 7500 Fast Real-time 
System (Invitrogen). Automated allele calling was performed by allelic discrimination plots 
using SDS 1.4 software (Invitrogen).
Pa t ients  and Methods
Pat ients  and t reatment
In the period between 2002 and 2008, a total of 115 pediatric patients were subsequently 
treated with high-dose MTX at the Radboud university medical center. Their characteristics 
and clinical data were collected retrospectively from medical files. Clinical data concerning 
MTX levels were available in 92 children: 49 patients with de novo ALL and 43 primary, 
high-grade osteosarcoma patients. Complete data regarding MTX-induced toxicity grades 
were available in 90 children (42 with ALL, 48 with osteosarcoma). The study was approved 
by the local ethics committee and written informed consent was obtained from parents 
and/or patients. Patients with osteosarcoma were treated with 12 courses of high-dose 
MTX (8–12 g/m2) according to the EURAMOS-1 protocol14. Patients with ALL were treated 
with four courses of high-dose MTX (5 g/m2) according to the Dutch ALL-10 protocol15. 
In all patients, high-dose MTX was followed by leucovorin rescue treatment (15 mg/m2). 
Additional leucovorin rescue was performed if the MTX concentration was ≥ 0.4 μmol/l at 
48 hours after administration. Interfering co-medication, such as trimethoprim and cipro-
floxacin, was stopped 72 h before the start of MTX infusion. 
MTX leve ls  and tox ic i ty
MTX concentrations were routinely determined by a fluorescence immunoassay. MTX plas-
ma levels at 48 hours after the start of each MTX-infusion were used for the analyses.
Toxicity grades after each high-dose MTX were registered in the period from start of the 
infusion until the next course of chemotherapy. We included leucopenia, neutropenia, 
trombopenia, anemia, epistaxis, mucositis, nausea, hepatotoxicity, nefrotoxicity, allergic 
reactions, and neurologic adverse events. Toxicity was graded according to the common 
terminology criteria for adverse events (CTCAE) of the National Cancer Institute (NCI) 
version 3.016. For analyses, toxicity grades were dichotomized: grade 0, 1 or 2 (no toxicity) 
versus grade 3 or 4 (toxicity).
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Resu l ts 
Characteristics and treatment variables for the 92 children are reported in Table I. In total, 
640 courses of high-dose MTX were evaluated, 193 courses in patients with ALL and 447 
courses in patients with osteosarcoma. Elevated MTX plasma levels of >0.4 µmol/l were 
seen after 173 MTX courses (27%) of which 26 (4%) had toxic values >1 µmol/l. MTX-in-
duced toxicity grade 3 or 4 was recorded in 91 courses of which only 38 (41.8%) were as-
sociated with a MTX plasma level of >0.4 µmol/l. Thus in 53 courses a grade 3 or 4 toxicity 
was seen with MTX plasma levels <0.4 µmol/l.
Table I. Characteristics and treatment variables for 640 courses of HD-MTX in 49 ALL and 43 
osteosarcoma patients
Median Range
Age at diagnosis (in years)  
 ALL 5.9 1.2-13.6
 Osteosarcoma 13.9 7.8-19.1
Number of HD-MTX courses  
 ALL 4 3-4
 Osteosarcoma 10 7-12
MTX Cumulative Dose (g/m2)  
 ALL 16 12.8-20
 Osteosarcoma 117 21.1-144
MTX plasma level at 48 hours (µmol/l)  
 ALL 0.35 0.25-0.38
 Osteosarcoma 0.21 0.16-0.34
  
Toxicity grade 3 or 4 N/total Percentage
 ALL 20/48 41.7%
 Osteosarcoma 16/42 38.1%
Table II shows the results of the genetic association analyses. Three SNPs (ABCC2 
c.1058G>A, ABCC1 c.3046-u1960G>A and GGH c.174 G>A) were excluded from analyses 
due to minor allele frequency (MAF) <5%; all SNPs were in Hardy-Weinberg equilibrium 
(HWE). None of the measured polymorphisms was associated to MTX plasma levels with 
p<0.05. In total, four polymorphisms showed an association with MTX plasma levels with 
p-value <0.10: ABCC2 c.3972C>T, AMPD1 c.34C>T, ITPA c.94C>A, GSTT1 gene deletion. 
Genet i c  assoc ia t ion  ana lys i s
Only polymorphisms with minor allele frequency of >0.05 and in Hardy-Weinberg equilib-
rium (p-value >0.05) in the studied patient population were included in the analysis. The 
effect of the polymorphisms on MTX plasma concentration 48 hours after infusion was eval-
uated using a generalized estimating equation (GEE) analysis. This is an extended linear 
regression analysis in which correlations among repeated measurements obtained from 
individual subjects over time are taken into account. Regression coefficients and corre-
sponding 95% confidence intervals (CI) were generated for each polymorphism under the 
assumption of an additive model (i.e. genotypes coded as 0 [homozygous most frequent 
genotype], 1 [heterozygous genotype] and 2 [homozygous least frequent genotype]; 
and included as continuous parameter); the resulting regression coefficient indicates the 
change in MTX levels associated with the minor allele. For the toxicity outcome, odds ratios 
(ORs) and 95% CIs were computed using logistic regression analysis, with the dependent 
variable being the highest grade of toxicity (dichotomized) according CTCAE criteria re-
corded throughout the treatment. Reported p-values are two-sided and are considered 
statistically significant if <0.05. Statistical analyses were conducted using Stata (version 
11.2) and SPSS (version 16.0, SPSS, Chicago, IL, USA).
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Table IV. Association with toxicity for four SNPs suggestively associated to MTX plasma levels
 Patients with toxicity grade
SNP Genotype 1 or 2 (N) 3 or 4 (N) OR 95% CI p-value
ABCC2 CC 17 14 1.00 - -
3972C>T CT 27 13 2.40 0.22-1.54 0.22
 TT 5 1 4.10 0.03-2.33 0.27
AMPD1 CC 37 26 1.00 - -
34C>T CT 13 8 0.88 0.32-2.4 0.79
 TT 1 0 - - -
ITPA CC 30 46 1.00 - -
94C>A CA 4 4 1.53 0.36-6.60 0.56
 AA 0 1 - - - 
GSTT1 0 copies 14 8 1.00 - - 
deletion 1 copy 21 21 0.44 0.09-2.03 0.29
 2 copies 12 3 1.75  0.61-5.04 0.30
Table III shows the results for these polymorphisms in more detail. Indications for a 
non-additive model were observed for ITPA c.94C>A and the GSTT1 gene deletion. Nota-
bly, missing rates for ABCC2 c.3972C>T and the GSTT1 gene deletion were high (results 
for 15 and 13 patients missing, respectively).
Table III.  
Genotypic regression coefficients for four SNPs associated with MTX plasma levels (with padditive <0.10)
SNP Genotype N Coefficient 95% CI p-value
ABCC2 CC 31 - - -
3972C>T CT 40 0.11 0.063-0.291 0.21
 TT 6 0.22  0.059-0.379 0.01
AMPD1 CC 63 - - -
34C>T CT 21 -0.11 -0.221-0.000 0.06
 TT 1 -0.23 -0.317-0.138 0.00
ITPA CC 76 - - -
94C>A CA 8 0.26 -0.079-0.605 0.13
 AA 1 0.21 0.139-0.277 0.00
GSTT1 0 copies 15 - - -
deletion 1 copy 42 0.04 -0.137-0.213 0.67
 2 copies 22 -0.12 -0.260-0.02 0.10
Association analyses for the four polymorphisms regarding MTX-induced toxicity (grade 3 
or 4 vs. 0, 1 or 2) showed no statistically significant association (Table IV). Directionality of 
effect given the association results for MTX levels fitted expectations for ABCC2 c.3972C>T 
and AMPD1 c.34C>T, but not for ITPA c.94C>A and the GSTT1 gene deletion.
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leading to elevated plasma levels and increased toxicity which is in contrast to the data 
of this study. The ITPA gene encodes for an inosine triphosphate pyrophosphatase. It has 
been shown that the ITPA c.94C>T polymorphism causes an amino-acid change (P32T), 
reducing ITPA enzymatic activity to 25% in heterozygotes, and abolishing it in homozygous 
variant21. Individuals with an homozygous variant might have less ability to metabolize 
MTX and therefore higher plasma levels which is in line with our findings. Furthermore, 
this variant has been found to influence the efficacy of MTX treatment of rheumatoid 
arthritis22 and ALL23 which could not be confirmed with our data.
In this study, we focused on candidate genes and polymorphisms that are likely to 
have a direct impact on the function of the gene as to increase our chance to identi-
fy relevant variants. We optimized our power by using data on available repeated mea-
sures of MTX plasma levels and by combining the results for osteosarcoma and ALL 
patients. Obvious pitfalls include the lack of power due to small sample size, potential 
inadequate pre-selection of candidate genes, unexplored heterogeneity in SNP effects for 
ALL and osteosarcoma patients. Nevertheless, our results can provide an incentive for fu-
ture studies into pharmacogenetics of MTX in childhood cancer. These studies would ideally 
include pharmacokinetic parameters and functional validation. 
Discuss ion
Understanding individual variation in drug response and toxicity is one of the major challenges 
in cancer research today. While MTX is highly effective within the putative cytotoxic range, it 
is also associated with significant toxicity. In ALL and osteosarcoma, tools to identify patients 
at risk for toxic MTX plasma concentrations and MTX toxicity may allow treatment adaption 
by dose-adaption. The interpatient variability of the MTX metabolism makes it however hard 
to find the right balance between effectiveness and toxicity and it seems that monitoring 
MTX plasma levels alone is not enough as even patients with adequate MTX plasma levels 
can develop serious MTX toxicity. We are one of the first to study the association between 
germline variation in folate and MTX related genes in combination with toxicity in childhood 
cancer. This study was of exploratory nature but led to some interesting findings that warrant 
further replication. 
Both ABCC2 c.3972C>T and AMPD1 c.34C>T were suggestively associated with an in-
creased elimination of MTX 48 hours after infusion and a lower risk to develop high grade 
toxicity. ABCC2 codes for the multidrug resistance protein 2 (MRP2/ABCC2) which is the 
key actor for the biliary excretion of MTX. Decreased transport of MTX into the bile by 
ABCC2 leads to an increased transport back into the circulation by ABCC3 causing in-
creased MTX plasma concentrations17. However, functional studies on the effect of the 
genetic variant in ABCC2 have not been published. In contrast to our data, the c.3972 T 
allele was significantly associated with increased MTX levels at 48 hours in the study of Rau 
and colleagues in 44 patients with ALL11. In a pharmacokinetic study where MTX elimina-
tion and distribution was studied via a multi-compartment model in 45 ALL patients, this 
polymorphism had however no significant influence on MTX pharmacokinetic parameters18. 
The AMPD1 gene encodes the enzyme adenosine monophosphate deaminase, which plays 
an important role in the purine nucleotide cycle. The c.34C>T variant causes a premature 
stop in the protein, leading to a nonfunctional AMPD1 enzyme. In contrast to our study, 
in patients with rheumatoid arthritis the presence of this variant showed no influence on 
the MTX plasma concentration but an association with central nervous system adverse 
effects19. There are no published data on the influence of AMPD1 c.34C>T regarding high-
dose MTX plasma levels or MTX-induced toxicity in patients with cancer. 
We also found indications for a role of the ITPA c.94C>A variant and GSTT1 copy number 
on MTX plasma levels. However, their effect on toxicity was not in line with the plasma 
level results. Patients with a complete deletion of GSTT1 showed lower MTX plasma levels 
at 48 hours after infusion but had an increased risk to develop MTX-related toxicity. In 
contrast, the ITPA c.94C>A variant was associated with higher MTX plasma levels at 48 
hours after infusion but no effect on the development of MTX-induced toxicity was seen. 
In general, glutathione S-transferases (GSTs) are linked to the development of cytotoxicity 
of chemotherapeutic drugs, including alkylating agents such as MTX20. It might be expect-
ed that patients with a complete deletion of GSTT1 have a reduced metabolism of MTX 
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In t roduct ion
Hepatotoxicity is one of the most common side effects of methotrexate (MTX) and occurs 
in 15-50% of patients but is usually transient and rarely results in chronic liver disease1. 
However, if the levels of the liver enzyme Alanine Transferase (ALT) have not normalized 
before the start of the next treatment course, chemotherapy generally is postponed and/or 
reduced. Reduction of chemotherapy might increase the risk of recurrence of the disease2. 
Predicting which patients are at risk for MTX-induced hepatotoxicity is not possible due 
to the unexplained inter-patient variability in pharmacokinetics and pharmacodynamics 
of MTX. Several studies have suggested that pharmacogenetics may have an additional 
value to explain this inter-patient variability and might be useful to identify patients at 
risk. A large number of studies have shown that the clinical variation in response to MTX 
is associated with polymorphisms in genes involved in MTX degradation and processing3-5. 
The most widely studied single nucleotide polymorphism (SNP) with respect to MTX me-
tabolism is the 677C>T variant in the methylenetetrahydrofolate reductase (MTHFR) gene. 
MTHFR is a key enzyme for intracellular folate homeostasis and metabolism. The T allele of 
the genetic variant is associated with decreased activity of the enzyme MTHFR resulting in 
low folate levels6. Based on these data, it has been suggested that patients with reduced 
MTHFR enzyme activity are more susceptible to toxicities from MTX. Several studies have 
indeed described an increased risk of toxicity7,8. However, not all studies have been able to 
link presence of the 677 T allele to an increased risk of MTX-induced toxicity9-11. 
As data published regarding the role of the MTHFR 677 polymorphism are contradictive, we 
analyzed the association between the MTHFR 677C>T SNP and hepatotoxicity in a Dutch 
cohort of cancer patients treated with high dose MTX. In addition, a meta-analysis includ-
ing a total of 1044 patients was performed and potential causes of the heterogeneous 
results between different studies were explored. 
Abs t rac t
Methotrexate (MTX), one of the important pillars in the treatment of different forms of can-
cer, is associated with the development of hepatotoxicity.  The 677C>T variant (rs1801133) 
in the methylenetetrahydrofolate reductase (MTHFR) gene might affect the development of 
hepatotoxicity. Results in literature are, however, contradictive. The aim of this study was 
to evaluate the role of the MTHFR 677C>T polymorphism in MTX-induced hepatotoxicity by 
analyzing a Dutch cohort of pediatric patients treated with high doses of MTX and subse-
quently performing a meta-analysis.
Ninety-eight patients receiving 542 courses of high-dose MTX were genotyped for the MTH-
FR 677C>T variant. Hepatotoxicity was evaluated retrospectively according to CTCAE-NCI 
criteria. The influence of MTHFR 677C>T on hepatotoxicity was examined using a gener-
alized estimating equation analysis (GEE). A fixed-effect meta-analysis based on this and 
previous studies investigating the association between the MTHFR 677C>T polymorphism 
and uniformly coded hepatotoxicity was performed. The GEE analysis showed an increased 
risk of developing hepatotoxicity for T- versus C-allele (odds ratio (OR) 1.8; 95% confi-
dence interval (CI) 1.0-3.2, p=0.04). This finding was not supported by the meta-analysis 
including seven studies and 1044 patients; the OR for the 677 T versus C allele was 1.1 
(95% CI 0.84-1.5, p=0.25). Heterogeneity between studies was observed, possibly related 
to differences in MTX dose and leucovorin rescue. In conclusion, in patients with cancer the 
MTHFR 677T allele has only a minor role in the development of MTX induced hepatotoxicity. 
Observed heterogeneity between studies warrants further study into (tailored) leucovorin 
rescue.
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SNP ana lys i s
The effect of the MTHFR polymorphism on the dichotomized toxicity variable was evaluated 
using a generalized estimating equation analysis (GEE), an extended regression analysis in 
which correlations among repeated measurements obtained from individual subjects over 
time were taken into account. Reported p-values are two-sided and are considered statisti-
cally significant if <0.05. Statistical analyses were conducted using Stata (version 9.2) and 
SPSS (version 16.0, SPSS Inc, Chicago, Il).
Meta-ana lys i s
We searched PubMed for papers before December 2010 using the keywords: ‘MTHFR 
C677T’, ‘cancer’ and ‘toxicity or hepatotoxicity’ (Figure I). Thirty-two articles were iden-
tified. References listed in the identified articles and reviews were used to find additional 
studies. All articles were screened for relevance to MTX-induced hepatotoxicity in oncology 
patients. Meta-analysis was performed on those studies evaluating the association of the 
MTHFR 677C>T polymorphism and MTX in Caucasian adults or pediatric patients with 
cancer. 
Pa t ients  and Methods
Pat ients  and t reatment
The patient population in this study comprised a total of 115 Dutch pediatric oncology 
patients treated at Radboud University Medical Center from November 2001 until January 
2008. These include 63 newly diagnosed, high-grade osteosarcoma patients and 52 pa-
tients with de novo acute lymphoblastic leukemia (ALL). The study was approved by the 
local ethics committee of the Radboud University Medical Center and written informed con-
sent was obtained from parents and/or patients. Patients with osteosarcoma were treated 
with 12 courses of high-dose MTX (8-12 g/m2) according to the EURAMOS-1 protocol12. 
Patients with ALL were treated with 4 courses of high-dose MTX (5 g/m2) according to 
the Dutch ALL-10 protocol13. In all patients high-dose MTX was followed by leucovorin 
rescue treatment (15 mg/m2). If the MTX concentration was higher than 0.4 µmol/L at 
48 hours after administration, additional leucovorin rescue was performed. Interfering co-
medication, such as trimethoprim and ciprofloxacin, was stopped 72 hours before the start 
of MTX infusion. The patient characteristics and clinical data were collected retrospectively 
from medical files. 
Tox ic i ty 
ALT activity was used to assess hepatotoxicity. Peripheral blood samples for measurement 
of ALT were obtained with each chemotherapy course at 48 hours after the start of the MTX 
infusion. Toxicity was graded according to the common terminology criteria for adverse 
events (CTCAE) of the National Cancer Institute (NCI) version 3.014. For analyses, toxicity 
grades were dichotomized: grade 0, 1 or 2 versus grade 3 or 4. 
Genotype ana lys i s
DNA was extracted from blood using the QIAamp DNA Blood Midi kit (Qiagen Inc., Va-
lencia, CA. USA) according to the manufacturers’ protocol. DNA of saliva (2 ml) collect-
ed in the Oragene saliva collection kit (DNA Genotek, Kanata, Ontario, Canada) was 
isolated using the Oragene DNA purification protocol as supplied by the manufacturer. 
The polymorphism 677C>T (rs1801133) in MTHFR was genotyped using Taqman® allel-
ic discrimination assays according to the protocol of the manufacturer (Applied Biosys-
tems, Nieuwerkerk aan den Ijssel, The Netherlands (assay ID C___1202883_20). After 
amplification the fluorescent signal for allelic discrimination was determined using the 
7500 Fast Real-time System (Applied Biosystems). Automated allele calling was per-
formed by allelic discrimination plots using SDS 1.4 software (Applied Biossystems). 
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Resu l ts
Pat ients 
Clinical data concerning MTX-induced hepatotoxicity and adequate samples for genotyping 
were available for 49 patients with osteosarcoma and 49 patients with ALL. The patient 
characteristics are reported in Table I. In total, 542 courses of high-dose MTX were evalu-
ated. Hepatotoxicity grades 3 or 4 according to the NCI criteria were seen in 160 courses of 
37 different patients, predominantly among patients with osteosarcoma (34 of 49 patients 
with osteosarcoma vs. 3 of 49 patients with ALL, p=0.001). The median time to occurrence 
of severe hepatotoxicity was after the third course of MTX (range 1st-7th course). 
SNP assoc ia t ion  ana lys i s
The MTHFR 677C>T allele and genotype frequencies were consistent with previous pub-
lished reports15 and were in Hardy-Weinberg equilibrium. Thirty-eight patients (38.7%) 
carried a heterozygous genotype (CT), 8 patients (8.2%) were homozygous TT, and 52 
patients (53.1%) carried the CC genotype. Genotype frequencies were similar but not the 
same in the ALL and osteosarcoma groups (Table I). 
Table I. Characteristics of patients and treatment variables
ALL Osteosarcoma
Age at diagnosis (years)  
   median (range) 5.9 (2.1-13.6) 13.9 (7.8-19.0)
MTX cumulative dose (g/m2)  
   median (range) 16 (5-20) 117 (30-144)
MTX courses  
   median (range) 4 (1-4) 7 (2-12)
Hepatotoxicity grade 3-4  
   number (%) 3 (6%) 34 (69%)
MTHFR 677C>T  
   CC n (%) 28 (57.1%) 24 (48.9%)
   CT n (%) 18 (36.7%) 20 (40.8%)
   TT n (%) 3 (6.1%) 5 (10.2%)
Figure I. Flow chart showing paper selection and exclusion for the meta-analysis
 Studies  
identified  
(N=34) 
Studies 
excluded  
(N= 28) 
Studies included 
in meta-analysis  
(N=6) 
• 'MTHFR C677T' and 'cancer' and 'toxicity' (N=29) 
• 'MTHFR C677T' and 'cancer' and 'hepatotoxicity' (N=3) 
• References (N=2) 
• Review (N=4) 
• Case report (N=3) 
• MTX not part of treatment (N=6) 
• No data concerning hepatotoxicity (N=6) 
• Other ethnicity (N=5) 
• Studies  concerning bone marrow 
transplantation (N=3) 
• No answer to request (N=1) 
Because of different definitions of hepatotoxicity, corresponding authors of these studies 
were contacted for data on genotype frequencies in patients with and without hepatotoxic-
ity according to the dichotomized CTCAE-NCI toxicity grades. The highest grade of CTCAE 
toxicity observed in each patient during the therapy period was recorded. Allelic odds 
ratio (OR) and 95% confidence interval (CI) were estimated using a fixed-effects model. 
The studies were weighed using the inverse variance method where larger studies with 
smaller standard errors have more weight than smaller studies with larger errors (Review 
manager 5.0, The Cochrane Collaboration, Oxford, UK). In addition, subgroup analyses 
were conducted by age and MTX dosage. Heterogeneity among studies was examined 
with I2 statistics that can be interpreted as the proportion of total variation contributed by 
between-study variation. 
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It is reasonable to expect that the MTHFR 677C>T polymorphism has a different effect on 
different types of cancer. Therefore, the type of cancer was taken in consideration in the 
GEE-analysis. The GEE analysis on the effect of the MTHFR polymorphism on the dichot-
omized toxicity variable after adjustment for type of cancer (i.e. osteosarcoma or ALL) 
showed a higher risk of developing hepatotoxicity in the CT (OR=1.8; 95% CI: 0.76-4.2, 
p=0.19) and TT (OR=3.3; 95% CI: 0.97-11.0, p=0.06) patients compared to the reference 
CC group, though not statistically significant. The analysis under an additive model showed 
a 1.8-fold increased risk for the T vs. the C allele (95% CI: 1.0-3.2, p=0.044). The effect 
was predominantly seen in patients with osteosarcoma where the T-allele was associated 
with a 1.9-fold increased risk of developing hepatotoxicity (95% CI: 1.0-3.5, p=0.050); 
in the ALL group we found a non-statistically significant 1.3-fold increased risk (95% CI: 
0.28-6.4, p=0.72) of developing hepatotoxicity for the T versus C allele. 
Meta-ana lys i s
Of the 32 studies identified in the literature, 7 discussed the 677C>T polymorphism in rela-
tion to MTX-induced hepatotoxicity in a Caucasian population (Figure I). The corresponding 
authors of 6 studies were willing to reclassify their data and stratify according to the NCI 
criteria as described above4,7,9,16-18. However, this information was only available in a sub-
set (N=1044) of all patients (N=1394) included in these seven studies including our own 
study. Table II shows the conclusions of the initial studies as well as the number of patients 
per study that were included in the meta-analysis. Included studies varied in age, type of 
cancer, MTX doses and frequency of hepatotoxicity.
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Discuss ion
In the present study, we investigated whether the MTHFR 677C>T geno type was associat-
ed with MTX-induced hepatotoxicity in pediatric patients with cancer. Analyses of our data 
on 98 patients showed analogue to published data indecisive results. Patients carrying 
the 677TT-genotype showed a clear trend, although statistically not significant, increased 
risk to develop hepatotoxicity. Furthermore, this effect was mainly seen in the group of 
patients with osteosarcoma who were treated with very high doses of MTX (cumulative 
dose range: 30-144 g/m2) compared to ALL patients (cumulative dose range: 5-20 g/m2). 
A possible explanation for the more modest effect observed in the ALL patients could be 
that in patients with a lower dose of MTX the leucovorin rescue of non malignant cells might 
be efficient enough to compensate the negative effect of reduced MTHFR activity. It has 
been shown that adequate folate levels can reduce or even normalize the effects related to 
the MTHFR polymorphism19. Additional folate supplementation after higher doses of MTX 
may therefore counteract the effect of a reduced MTHFR activity. Thus the combination of 
higher doses of MTX and insufficient rescue of non-malignant cells may lead to a higher risk 
of developing hepatotoxicity in patients carrying the 677TT-genotype. This explanation is 
supported by a recent study by Chiusolo et al. suggesting that intensive leucovorin rescue 
after high-dose MTX abrogates the effect of the MTHFR 677C>T variant20. 
The second part of our study concerned a meta-analysis of 6 previously published studies 
and our own study. Overall, the meta-analysis did not show an association between the 
MTHFR 677C>T variant and low (0, 1 and 2) and high-grade (3, 4) MTX-induced hepato-
toxicity (OR 1.1, 95% CI: 0.84-1.5). We did not find statistically significant heterogeneity 
between study results but inspection of the effect estimates showed large differences in 
point estimates, despite of uniform reclassification of toxicity grading. Several factors, 
including differences in patient characteristics and/or treatment protocols, may be the 
cause of this difference. Results of our meta-analyses were stratified for age showing no 
association between age and development of hepatotoxicity. Another difference might be 
that the studies in the meta-analysis included patients with three different types of cancer. 
However, it is reasonable to expect the effect of a germline genetic variant in a drug me-
tabolizing gene to be independent of the type of malignancy. Indeed, the MTHFR 677C>T 
variant has been associated with decreased activity of MTHFR and prolonged low folate 
state in affected patients in different kind of diseases21,22. A patient was either classified 
as positive or negative for hepatotoxicity based on the highest CTCEA grade experienced 
during the treatment period. Although this reclassification resulted in homogeneous tox-
icity grading over studies, it does not fully capture the experienced toxicity per patient. 
This inaccuracy in phenotype classification may have also contributed to heterogeneity 
between study estimates. Gender has recently been pointed out by several authors as an 
important factor interacting with MTHFR polymorphism in producing a phenotypic effect on 
Based on the reclassified toxicity data, allelic ORs were recalculated for each individual 
study (Figure II). When assessed in combination with the results of this study, no signif-
icant association between the 677C>T variant and hepatotoxicity was seen (OR T vs. C 
allele=1.1, 95% CI: 0.84-1.5, p=0.25). The heterogeneity test showed a non-statistically 
significant heterogeneity with an I2 of 24%. 
Figure II.  
Meta-analysis of the association between the MTHFR 677C>T variant and the risk for hepatotoxicity
Study or Subgroup log [OR] SE Weight Odds Ratio
G 3-4 G 0-2 IV, Random, 95% CI
Aplenc, 2005 0 0.14 362 602 39.4% 1.00 [0.76, 1.32]
Chiusolo, 2007 1.992 1.1114 12 30 1.6% 7.33 [0.83, 64.74]
Costea, 2007 -0.0305 0.2284 240 132 24.2% 0.97 [0.62, 1.52]
Gemmati, 2007 0.3646 1.4146 2 134 1.0% 1.44 [0.09, 23.04]
Hagleitner, this study 0.5988 0.2876 74 122 17.7% 1.82 [1.04, 3.20]
Ongaro, 2009 0.1989 0.6087 12 168 5.0% 1.22 [0.37, 4.02]
Patino-Garcia, 2009 -0.3147 0.3899 36 162 11.0% 0.73 [0.34, 1.57]
Total (95% CI) 738 1350 100.0% 1.12 [0.84, 1.48]
Heterogeneity: Tau²=0.03; Chi²=7.87, df=6 (P=0.25); I²=24%
Test for overall effect: Z=0.77 (P=0.44)
Odds Ratio
OR develoment of hepatotoxicity
IV, Random, 95% CI
Hepatotoxicity
Additionally, we performed a meta-analysis stratified for gender (males OR=1.06, 95% CI: 
0.73-1.53, p=0.76 and females OR=1.71, 95% CI: 1.04-2.81, p=0.03).
Next we also stratified the cohorts based on MTX dosage (MTX 15-30 mg/m2/course and 
MTX 4-14 g/m2/course). In both groups the MTHFR 677C>T variant did not affect hepa-
totoxicity risk (15-30 mg/m2/course, N=932, OR=1.34, 95% CI: 0.83-1.3, p=0.75; and 
4-14 g/m2/course, N=462, OR=1.04, 95% CI: 0.83-1.30, p=0.75). Furthermore, we 
assessed differences in the association with hepatic toxicity between pediatric and adult 
patients. This analysis showed that the MTHFR 677C>T variant was not associated with 
hepatic toxicity in pediatric patients (N=734; OR=0.99 (95% CI: 0.79-1.25, p=0.95). In 
adult patients, a non-statistically significant increased risk was observed (N=198; OR=2.14 
(95% CI: 0.82-5.61, p=0.12). 
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the patients from cancer susceptibility23 to migraine24. Our subgroup analyses by gender 
indeed showed a significant association between the MTHFR T-allele and hepatotoxicity 
for females. However, our results also show a wide 95% CI which might be explained by 
less females (38.8%) included in the studies compared to males (61.2%). As far as we 
know this is the first meta-analysis showing a significant interaction between the MTHFR 
genotype, gender and MTX toxicity. However, this needs to be confirmed in further studies.
Therapy-related factors that may contribute to heterogeneity in results include differences 
in dosage and duration of therapy, co-medication and presence of leucovorin rescue. First-
ly, in four of the seven studies MTX was given on a weekly basis with doses between 15-30 
mg/m2 for 2-3 years without leucovorin rescue7,9,17,18. In the other three studies, including 
this study4,16, MTX was administered at a dose of 4-14 g/m2. Sub-analysis according to 
MTX doses did however show absence of effect of the polymorphism in both the low (15-30 
mg/m2/course) and high dose (4-14 g/m2/course) group. Therefore, our hypothesis that 
the observed difference between ALL and osteosarcoma in the relationship with MTHFR 
677C>T might be related to the different dosage of MTX, could not be confirmed by the 
meta-analyses. Secondly, all treatment protocols of patients with ALL consisted of daily 
oral mercaptopurine (6MP) during maintenance therapy. 6MP influences the pharmacoki-
netics and pharmacodynamics of MTX; hence, the recorded liver toxicity in ALL patients 
may be related to but not directly induced by MTX. Unfortunately, there are no reliable 
measures to determine whether 6MP or MTX is responsible for the development of toxici-
ties. However, a recent study showed that the increased risk of developing toxicity among 
patients with the 677TT-genotype is rather associated with MTX than 6MP25. Thirdly, leu-
covorin rescue was applied in our study and that of Patino-Garcia et al3. In the latter study 
50 mg/m2 folinic acid was administered every 6 hours up to 12 doses beginning 24 hours 
post-infusion of MTX. This is substantially higher than the dose used in our study where 
an initial dose of folinic acid of 15 mg/m2 every 6 hours was followed by leucovorin dose 
adjustment in accordance with serum MTX-levels at 48-hours post-infusion. This difference 
in leucovorin rescue may have influenced the effect of a reduced MTHFR activity in patients 
with 677TT-genotype and might explain the higher hepatotoxicity risk for T-allele carriers 
in our study and the absence of an increased risk in the study by Patino-Garcia et al3.
Based on the analysis of our data on 98 MTX-treated pediatric cancer patients and the me-
ta-analysis we conclude that in patients with cancer the MTHFR 677T allele has a minor role 
in the development of MTX-induced hepatotoxicity. These results need to be interpreted 
cautiously, because they are based on a small number of studies with relatively few inci-
dences of hepatotoxicity, a dichotomized (though uniform) measure of toxicity, and there 
are indications of heterogeneity between studies, though not statistically significant. How-
ever, further study on the effect of leucovorin rescue on MTHFR activity and which patients 
may benefit from intensive leucovorin rescue is warranted. 
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Is there a role for the MTHFR 677C>T and the 1298 A>C polymorphism in 
methotrexate induced liver toxicity?
Fisher and colleagues performed a meta-analysis in RA patients1. They included in total 
eight different studies in which the 677C>T and 1298A>C genetic variants were studied in 
relationship to MTX induced toxicity.  In total 1400 patients were included in the analyses 
of the 677C>T variant and half of them were analyzed regarding the 1298A>C variant. 
Only a significant association could be found between the 677C>T variant and overall 
toxicity. The meta-analysis of Lee and colleagues2 included 1514 RA patients to study the 
relevance of the 677C>T and 1298A>C polymorphisms of MTHFR. They did not find any 
association between the occurrences of MTX induced toxicity and these genetic variants. 
Unfortunately, although the cohort of patients studied in both meta-analyses was relatively 
large, there was substantial heterogeneity between the patients cohorts included, which 
makes it difficult to definitely rule out a role of the MTHFR gene in MTX induced toxicities. 
Furthermore, in both meta-analyses it is not clear what kind of toxicities were studied 
as it is mentioned that any toxicity was the end point. In addition, differences in toxicity 
grading systems between the studies, differences in dosages of MTX used and finally dif-
ferences in folate rescue scheme make that these meta-analysis cannot be used to answer 
the question whether these genetic variants of the MTHFR gene are of clinical importance. 
Therefore meta-analyses performed in more homogenous groups of patients, receiving 
similar dosages of MTX and using same toxicity grading systems e.g. when MTX induced 
liver toxicity is being studied should be performed. 
A recent meta-analysis study by Owen and colleagues did follow such an approach3; they 
included 309 RA patients with well-defined toxicities due to MTX treatment. No association 
between the 2 functional MTHFR genetic variants and the occurrence of liver toxicity or oth-
er toxicities were found. Although this cohort was smaller than the previously mentioned 
studies, the cohort was homogenous, well defined regarding toxicity and similar ethnicity 
and is therefore very useful for a genetic association study. The clinical relevance of these 
data within the field of RA treatment is however debatable. In patients with RA dosages 
of MTX are much lower than those for cancer treatment. It is generally thought that es-
pecially these higher dosages of MTX are the trigger for MTX induced liver toxicity. For 
this reason, it is of utmost interest whether there are meta-analyses performed in cancer 
patients receiving these high dosages of MTX. Indeed, there are few genetic association 
studies investigating cancer patients for a relation between the MTHFR gene and MTX in-
duced toxicities. First of all, the study of Yang and colleagues4 including a cohort of patients 
with acute lymphoblastic leukemia, both adults and children, with different ethnicities and 
found a significant association between the 677C>T genetic variant and the occurrence 
of liver toxicity. In their statistical analyses they stratified patients regarding their eth-
nicity demonstrating that especially in Africans and Caucasians the risk of liver toxicity 
was high whereas Asians were not at risk. Interestingly, they also performed a stratifica-
tion regarding age and found that the occurrence of liver toxicity in association with the 
677C>T variant was predominantly found in adults and not in children. This is very inter-
esting as in the treatment of childhood acute lymphoblastic leukemia (ALL) high dosages 
Methot rexate  t reatment
Methotrexate (MTX) is an antimetabolite used in the treatment of different types of cancer 
and in a number of autoimmune diseases such as rheumatoid arthritis (RA). Interesting-
ly, the dosage used to treat patients varies substantially between the different types of 
diseases. Depending on the dosage given several forms of toxicity can be expected e.g. 
mucositis, bone marrow suppression and liver toxicity. These MTX-induced toxic effects 
can be reversed by the administration of leucovorin (5-formyltetrahydrofolate). This so-
called leucovorin rescue is part of the standard treatment when high doses of MTX are used 
which is mostly the case in the treatment of cancer and recommended in the treatment of 
autoimmune diseases where low doses MTX are given. Especially in cancer patients, MTX 
is given because of its ability to inhibit the folate pathway enzymes including the enzymes 
dihydrofolatereductase (DHFR) and methylenetetrahydrofolate reductase (MTHFR). The 
last one, and especially the gene coding for the MTHFR enzyme, has been studied several 
times regarding the relationship between toxicities caused by MTX and genetic variants 
present in this gene. It has been suggested that genetic variants of the MTHFR gene are 
associated with MTX induced liver toxicity, bone marrow suppression and the appearance 
of mucositis. The two most commonly studied genetic variants are the MTHFR 677C>T and 
1298A>C. Both variants are known to result in lower enzyme activity, which is probably the 
underlying cause of MTX related toxicity.
C l in i ca l  re levance  o f  the  677C>T and the 
1298A>C po lymorph ism in  MTX induced 
l i ver  tox i c i ty
Genetic association studies into the role of MTHFR and MTX-induced toxicities are mainly 
performed in patients with RA and cancer, therefore we will focus on these two diseases. 
There are several studies describing an association between the 677C>T genetic variant 
of the MTHFR gene and liver toxicity. However, there are also several studies showing no 
association at all. One of the main problems of these genetic studies are the number of 
patients included, heterogeneity of the study population, differences in ethnicity and the 
paucity of prospective studies with adequate toxicity registrations. The last one is in our 
opinion extremely important to definitely determine if the two most described genetic 
variants of the MTHFR gene are of clinical importance. Another way to gain insight wheth-
er genetic variants in the MTHFR gene are important in the development of toxicities is 
by combining several small scale studies in a meta-analysis. A PubMed search using the 
keywords: ‘MTHFR’, ‘toxicity or hepatotoxicity’ and ‘meta-analysis’ revealed six different 
meta-analysis regarding the role of the 677C>T and the 1298A>C variants in the MTHFR 
gene and MTX induced (liver) toxicity.
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the identification of genes associated with MTX related toxicities beyond the obvious candi-
date genes. In addition, it should be realized that the clinical relevance of pharmacogenetic 
studies can only be determined in large enough patient cohorts, followed by proper replica-
tion of identified associations and preferably by performing a prospective study.
Summary
Although many studies have been performed regarding the role of the 677 C>T and the 
1298C>A genetic variant versus MTX induced liver toxicity, no clear conclusion can be 
made yet.  Most meta-analyses performed demonstrate that there is no clear relationship 
between these genetic variants of the MTHFR gene and liver toxicity although there are 
meta-analyses suggesting there might be a minor role. It is clear that before pharma-
cogenetic results can be used for clinical practice, studies are being performed in large 
homogenous patient cohorts followed by replication of the results to identify the true value 
of the association found.
(3-5 g/m2) of MTX are used and in adults not (15-30 mg/m2). However, the number of 
patients studied was too small to make any definite conclusions. In a recent meta-analy-
sis study performed by Lopez-Lopez and colleagues5, children with ALL were investigated 
regarding the presence of the 677C>T and 1298A>C genetic variant of the MTHFR gene 
and the occurrence of MTX induced toxicity. They showed, as was suggested by the study 
of Yang and colleagues, that in this pediatric population, there is a lack of association be-
tween these genetic variants in children and MTX induced toxicity. Finally, a meta-analysis 
performed by our own group included more than 1000 patients with osteosarcoma and 
ALL6. They all received high dosages of MTX. Primary goal of this study was to answer the 
question whether or whether not the 677C>T variant is associated with the risk for liver 
toxicity due to MTX treatment. In all patients included, hepatotoxicity was evaluated retro-
spectively and uniformly classified according the National Cancer Institute criteria for ad-
verse events. No association was found between the presence of the genetic variant in the 
MTHFR gene and the development of liver toxicity. Although the cohort was large enough, 
all patients received high dose MTX and toxicities were reclassified using the same criteria 
for adverse events, this study has its limitations by its retrospective character, including 
patients treated in different countries and using different regimens of supportive care such 
as leucovorin rescue. Notably, in all meta-analysis studies discussed in this editorial, sev-
eral single cohort studies were repeatedly included in the different meta-analyses. There-
fore, to finally proof the association between genetic variants in MTHFR and MTX induced 
toxicity, a large prospective study, including a homogenous group of patients, treated ac-
cording the same protocols and prospectively classified according the same toxicity criteria 
is necessary.
Conc lus ions  and fur ther  
recommendat ions
Based on all studies performed so far, including the meta-analyses present in literature, 
one must conclude that it is still unclear whether the two most studied genetic variants 
(677C>T and 1298C>A) of the MTHFR gene, play a clinical significant role in the develop-
ment of MTX induced liver toxicity. Most meta-analysis performed showed no association 
between variants in MTHFR and MTX induced toxicities, suggesting that if there is a role of 
the MTHFR variants this will be very limited with questionable clinical relevance. Most prob-
ably MTX related toxicities have a multifactorial background meaning that they are induced 
by a combination of genetic and environmental factors. The pharmacological metabolism 
of MTX involves many transporters and enzymes that can influence MTX efficacy and tox-
icity. Future studies should focus more on these genes. Ultimately, if large enough patient 
cohorts are collected a hypothesis driven genetic approach would be the method of choice 
(e.g. genome-wide association study or next generation sequencing). Such study will allow 
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In t roduct ion
Cisplatin is an effective chemotherapeutic drug for several types of cancer such as ovari-
an cancer, lung cancer, osteosarcoma and neuroblastoma. Ototoxicity, characterized as a 
permanent, bilateral sensorineural hearing loss, is one of the most common side effects 
of cisplatin and occurs in 40-60% of patients1. Ototoxicity is one of the main reasons for 
dose reduction or termination of treatment with cisplatin treatment. Clinical risk factors for 
the development of cisplatin-induced ototoxicity have been described such as age younger 
than 5 years at diagnosis2,3, concurrent medication like carboplatin4 as well as higher cu-
mulative doses2,4, cranial radiation5 and pre-existing renal dysfunction. Nevertheless, these 
clinical factors are not sufficient to reliably predict ototoxicity before the start of treatment. 
A candidate gene study in 166 pediatric patients suggested that genetic variants in the 
genes encoding thiopurine S-methyltransferase (TPMT) and catechol O-methyltransferase 
(COMT) can predict the development of cisplatin-induced ototoxicity and may explain the 
interindividual variability6. Two recently published studies, developed to validate these find-
ings, showed inconsistent results. Pussegoda and colleagues confirmed the findings of Ross 
et al. for variants in the TPMT gene in a cohort of 155 patients however, with smaller effect 
sizes compared to the original findings7. In contrast, no association of TPMT or COMT and 
ototoxicity was found in a cohort of 213 patients with medulloblastoma8. Based on these 
three studies no recommendation for clinical implementation regarding genetic variants in 
TPMT and COMT and ototoxicity can be made. The aim of the current study is to provide a 
clearer picture of the genetic impact of TPMT and COMT variants on developing cisplatin-in-
duced ototoxicity. Therefore we investigated two independent cohorts of 110 Dutch and 38 
Spanish patients with osteosarcoma and performed a meta-analysis including previously 
published studies6-8 resulting in a total population of 664 patients with cancer.
Abs t rac t
Treatment with cisplatin-containing chemotherapy regimens causes hearing loss in 40-
60% of cancer patients. It has been suggested that genetic variants in the genes encod-
ing thiopurine S-methyltransferase (TPMT) and catechol O-methyltransferase (COMT) can 
predict the development of cisplatin-induced ototoxicity and may explain interindividual 
variability in sensitivity to cisplatin-induced hearing loss. Two recently published studies 
however, sought to validate these findings and showed inconsistent results. The aim of this 
study was to evaluate the role of polymorphisms in the TPMT and COMT genes in cispla-
tin-induced ototoxicity. Therefore we investigated two independent cohorts of 110 Dutch 
and 38 Spanish patients with osteosarcoma and performed a meta-analysis including all 
previously published studies resulting in a total population of 664 patients with cancer. 
With this largest meta-analysis performed to date, we show that the influence of TPMT and 
COMT on the development of cisplatin-induced hearing loss may be less important than 
previously suggested.
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Genotyp ing
Previously associated variants in TPMT (rs12201199: C__31923406_10, rs1800460: 
C__30634116_20, rs1142345: C_____19567_20) and COMT (rs4646316: 
C__29193982_10, rs9332377: C__29614343_10) were genotyped using Taqman allelic 
discrimination assays according to the protocol of the manufacturer (Invitrogen, Bleiswijk, 
The Netherlands). After amplification, the fluorescent signal for allelic discrimination was 
determined using the 7500 Fast Real-time System (Invitrogen). Automated allele calling 
was performed by allelic discrimination plots using SDS 1.4 software (Invitrogen).
SNP ana lys i s
In both cohorts, statistical differences regarding demographic data between patients who 
developed hearing loss (cases; >20 dB hearing loss above 4 kHz) and patients without 
hearing loss (controls; ≤20 dB hearing loss at all frequencies) were assessed by the Fischer 
exact test. Reported p-values are two-sided and are considered statistically significant if 
<0.05. Associations between ototoxicity and potential confounders, such as age, gender, 
cumulative dosage of cisplatin and concomitant drugs were evaluated using a 2x2 table (in 
case of dichotomized variables) or linear regression (in case of linear variables) in SPSS 
version 20 (SPSS Inc., Chicago, Il). To assess the effect of the genetic variants on ototox-
icity data were dichotomized in grade 0 vs. grade 2-4. Multivariate logistic regression anal-
yses included vincristine exposure as confounder in PLINK11 using the command-logistic.
Mater ia l s  and methods
Dutch  cohor t
A cohort of 110 Dutch patients with high-grade osteosarcoma treated with cisplatin was re-
cruited from the Radboud University Medical Center, the University Medical Center of Gron-
ingen and Leiden University Medical Center. All patients were treated with cisplatin with a 
median cumulative dose of 500 mg/m2 (range: 100 to 600 mg/m2). Of patients included 
audiometric analysis were available at diagnose, during therapy and after completion of 
therapy. Data concerning administration of other potentially ototoxic medications such as 
furosemide, vancomycin, gentamicin, tobramycin, amphotericin B, carboplatin and vincris-
tine, were recorded. In patients alive, DNA was extracted from blood using the QIAamp 
DNA Blood Midi kit (Qiagen Venlo, The Netherlands) or saliva (2 ml) using the Oragene DNA 
purification protocol (DNA Genotek, Kanata, Ontario, Canada). Of patients that passed 
away, (N=39, 26.5%, median follow up time 2.3 years with range 1.1-5.5 years), DNA of 
paraffin-embedded samples was extracted as recently described9. The study was approved 
by the ethics committee from the Radboud University Medical Center as the central com-
mittee for this study for the Netherlands and written informed consent was obtained from 
parents and/or patients
Span ish  cohor t
To enlarge sample size for meta-analyses, we additionally included an independent Span-
ish cohort of osteosarcoma patients who were treated with cisplatin-containing regimens. 
To prevent population bias, this cohort was analyzed separately. In total, 38 patients with 
osteosarcoma were included on the basis of availability of germline DNA and audiologic 
assessment at least one month after initial treatment. Data regarding ototoxic medication 
were available. The study was approved by the local ethics committee from the University 
of Navarra and University Clinic in Pamplona. Written informed consent was obtained from 
parents and/or patients.
Ototox ic i ty
In both cohorts audiologic evaluations were prospectively performed at diagnosis, during 
therapy and after completion of therapy. First audiological follow-up was performed 1-3 
months after completion of therapy and thereafter annually. All audiometric assessments 
were age appropriate performed by conventional or play audiometry under standardized 
conditions as part of routine clinical monitoring for cisplatin-related hearing loss. Hearing 
loss was retrospectively classified according to two grading systems: the National Can-
cer Institute CTCAE version 3.0 (http://ctep.cancer.gov/forms/CTCAEv3.pdf) and the new 
SIOP Boston ototoxicity scale which classifies hearing loss on the basis of absolute hearing 
levels in 4 grades10. The most recent audiologic assessment during follow-up period after 
the last cisplatin course was used for analysis. 
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patients graded according the CTCAE criteria (0 vs. >25 dB at 4-8 kHz) and 22 according to 
the SIOP criteria (0 vs. >20 dB at 4-8 kHz). Univariate analysis showed no association with 
non-genetic factors previously reported to be associated with ototoxicity: age (p=0.73) 
and cumulative dose of cisplatin (p=0.99).
Span ish  cohor t
To enlarge sample size for the meta-analyses we included another cohort 
of 38 Spanish patients of European ancestry with osteosarcoma (Table I). No statistically 
significant differences concerning age, gender or cumulative dose of cisplatin was seen 
between patients with hearing loss (cases; >20 dB hearing loss above 4 kHz) and pa-
tients with normal hearing (controls; ≤20 dB hearing loss at all frequencies). None of the 
included patients was additionally treated with cranial irradiation. Regarding concomitant 
medication, all but 6 patients were additionally treated with vincristine and 23 patients 
received ototoxic antibiotics, such as vancomycin, gentamicin or tobramycin. In univariate 
analysis the use of these antibiotics was not a confounding factor to develop ototoxicity 
in this cohort (p=0.74). As to the small sample size and to prevent population bias due to 
ethnicity, genotyping results of this cohort were analyzed as an independent cohort in the 
meta-analyses. 
Meta-ana lyses
We searched PubMed for papers using the keywords: ‘ototoxicity’, ‘TPMT’ and ‘COMT’. Since 
the publication of Ross and colleagues6 in 2009 only 2 other studies7,8 evaluated the asso-
ciation of the COMT and TPMT variants in cancer patients. Meta-analysis was performed on 
these 3 previously published studies and the 2 cohorts presented in this study were includ-
ed. Of each of the 5 studies the CTCAE hearing loss criteria were used, excluding patients 
with grade 1 ototoxicity to better differentiate between cisplatin-induced ototoxicity and 
normal hearing. The studies were weighed using the inverse variance method, where larg-
er studies with smaller standard errors have more weight than smaller studies with larg-
er errors (Review manager 5.0, The Cochrane Collaboration, Oxford, UK). Heterogeneity 
among studies was examined with I2 statistics that can be interpreted as the proportion of 
total variation contributed by between-study variation. Allelic odds ratio (OR) were recalcu-
lated dependent on the number of cases and controls in each cohort and 95% confidence 
interval (CI) were estimated using a fixed effects model or random effects models in case 
large heterogeneity I2 >50% was observed.
Resu l ts
Dutch cohor t
A total of 110 patients with Dutch ancestry and newly diagnosed osteosarcoma were in-
cluded of whom 42 (38.2%) developed >20 dB hearing loss above 4 kHz. Characteristics 
of patients divided in patients with hearing loss (cases; >20 dB hearing loss above 4 kHz) 
and patients without hearing loss (controls; ≤20 dB hearing loss at all frequencies) are 
depicted in Table I.
Baseline characteristics did not show statistically significant differences between the 2 
groups. None of the patients included was treated with cranial irradiation or with concom-
itant ototoxic antibiotics. Only 5 patients were additionally treated with vincristine. Other 
ototoxic chemotherapeutics were not administered. In 23 (20.9%) of all patients cumula-
tive dose of cisplatin was reduced due to ototoxicity (N=9, >20 dB hearing loss above 4 
kHz) or other cisplatin-induced toxicity (N=14). Baseline audiograms were available in 87 
patients (79%) showing normal baseline hearing thresholds (≤20 dB) in all patients. Me-
dian follow up period was 5.2 years (range 23 to 7763 days). Different ototoxicity grading 
systems were used to exclude biased dichotomisation. For the CTCAE criteria, 80 patients 
with baseline audiogram were included. Patients with grade 1 ototoxicity (N=7) were ex-
cluded in order to use same inclusion/exclusion criteria as previous studies in literature6-8. 
Classification according to the CTCAE criteria showed in all but 7 patients’ identical toxicity 
grades when compared to the SIOP grading system. Four patients with grade 1 and 3 pa-
tients with grade 2 ototoxicity according to the SIOP Boston ototoxicity scale were upgrad-
ed to grade 2 and 3 according the CTCAE criteria. Hearing loss grade 2-4 was seen in 23 
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Genotyp ing
We genotyped three variants in the TPMT gene (rs12201199, rs1800460, and rs1142345) 
and two in the COMT gene (rs4646316, rs9332377). No deviation from Hardy–Weinberg 
equilibrium was observed.  Irrespective of the grading system used (CTCAE or SIOP), 
association analysis  using an additive genetic model correcting for usage of vincristine, 
showed no association between genetic variants in TPMT or COMT with an increased  risk 
of ototoxicity in the Dutch cohort (Table II and Table III). 
Table II. Association analyses of the Dutch cohort – SIOP vs. CTCAE criteria
  SIOP Boston criteria CTCAE criteria
Gene SNP OR 95% CI p-value OR 95% CI p-value
TPMT rs1142345 0.96 0.30-3.08 0.95 0.71 0.15-3.26 0.66
 rs1800460 0.49 0.12-1.97 0.31 0.32 0.04-2.58 0.28
 rs12201199 0.65 0.22-1.91 0.44 0.74 0.20-2.76 0.65
COMT rs4646316 0.49 0.22-1.14 0.1 0.67 1.81-0.24 0.42
 rs9332377 0.8 0.41-1.55 0.51 0.91 0.41-2.04 0.83
Table III. Call rates of the Dutch and Spanish cohort for each variant according to the CTCAE  
ototoxicity criteria
Gene SNP Dutch Cohort, N=80 Spanish Cohort, N=34
TPMT rs1142345 69 32
 rs1800460 70 33
 rs12201199 72 34
COMT rs4646316 71 32
 rs9332377 80 33
Meta-ana lyses
So far, 3 studies with 4 independent cohorts studying the influence of TPMT and COMT on 
the development of ototoxicity have been published6-8. With this study we add two addi-
tional independent cohorts. In all studies the CTCAE criteria were reported. To better differ-
entiate between cases and controls all studies excluded patients with grade 1 ototoxicity. 
In total, 664 patients were included in the meta-analyses. Table IV shows the demographic 
data of the initial studies, as well as the number of patients per study that were included 
in the meta-analysis. In Figures I and II OR for each individual study are presented. The 
genetic variant rs4646316 in the COMT gene was the only significant association with oto-
toxicity (OR A vs. T allele=1.52, 95% CI: 1.16-1.99, P=0.003; Figure II). The heteroge- 
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Figure I. Forest plots of genetic variants in TPMT gene
TPMT rs12201199
Odds Ratio
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI
Ross, 2009, discovery 10 66 0 40 8.7% 15.05 [0.86, 264.32]
Ross, 2009, replication 18 146 1 72 12.7% 9.98 [1.31, 76.36]
Pussegoda, 2013 21 174 3 136 17.8% 6.08[1.78, 20.86]
Yang, 2013, radiation 29 254 16 122 21.5% 0.85 [0.44, 1.64]
Yang, 2013, no radiation 9 66 2 6 13.8% 0.32 [0.05, 1.98]
Hagleitner, this study, Dutch 3 38 11 106 17.1% 0.74 [0.19, 2.81]
Hagleitner, this study, Spanish 3 36 0 32 8.2% 6.79 [0.34, 136.71]
Total (95% CI) 780 514 100.0% 2.15 [0.74, 6.26]
Heterogeneity: Tau2=1.28; Chi2=20.01, df=6 (P=0.003); I2=70% 
Test for overall effect: Z=1.40 (P=0.16) No ototoxicity Ototoxicity
TPMT rs1800460
Odds Ratio
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI
Ross, 2009, discovery 8 66 0 40 10.3% 11.77 [0.66, 209.70]
Ross, 2009, replication 8 146 0 70 10.4% 8.65 [0.49, 152.09]
Pussegoda, 2013 13 174 3 136 21.8% 3.58 [1.00, 12.83]
Yang, 2013, radiation 8 254 8 122 24.4% 0.46 [0.17, 1.27]
Yang, 2013, no radiation 3 66 0 6 9.5% 0.72 [0.03, 15.45]
Hagleitner, this study, Dutch 1 36 0 30 8.8% 2.58 [0.10, 65.61]
Hagleitner, this study, Spanish 1 40 8 100 14.8% 0.29 [0.04, 2.44]
Total (95% CI) 782 504 100.0% 1.55 [0.50, 4.87]
Heterogeneity: Tau2=1.13; Chi2=13.08, df=6 (P=0.04); I2=54% 
Test for overall effect: Z=0.76 (P=0.45) No ototoxicity Ototoxicity
TPMT rs1142345
Odds Ratio
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI
Ross, 2009, discovery 8 66 0 40 9.3% 11.77 [0.66, 209.70]
Ross, 2009, replication 11 146 1 72 13.7% 5.79 [0.73, 45.72]
Pussegoda, 2013 16 174 3 136 20.1% 4.49 [1.28, 15.74]
Yang, 2013, radiation 9 250 9 124 22.8% 0.48 [0.18, 1.23]
Yang, 2013, no radiation 4 70 0 6 8.6% 0.88 [0.04, 18.22]
Hagleitner, this study, Dutch 2 40 7 98 17.0% 0.68 [0.14, 3.45]
Hagleitner, this study, Spanish 2 34 0 30 8.5% 4.69 [0.22, 101.72]
Total (95% CI) 780 506 100.0% 1.93 [0.66, 5.64]
Heterogeneity: Tau2=1.08; Chi2=14.29, df=6 (P=0.03); I2=58% 
Test for overall effect: Z=1.20 (P=0.23) No ototoxicity Ototoxicity
M-H, Random, 95% CI
Experimental Control
Odds Ratio
M-H, Random, 95% CI
Odds Ratio
M-H, Random, 95% CI
Experimental Control
Experimental Control
Odds Ratio
neity test showed a non-statistically significant heterogeneity with an I2 of 31%. Notably, 
there are substantial differences in the range of the ‘total events’ captured between the 
meta-analyses which is related to incomplete genotyping in all studies, except for the study 
of Pussegoda and colleagues. 
Table IV. Demographic data of patients with ototoxicity included for meta-analyses
 
Cases/Total 
cohort Age (y) Gender
Cumulative 
dose (mg/m2)
Cranial 
irrdiation
 N Median % Median %
Ross et al. 106/162 6 67% 400 mg/m2 18.5%
Pussegoda et al. 87/155 6 49.4% 400 mg/m2 18%
Yang et al., radiation cohort 131/195 7 68.8%* 300 mg/m2* 100%*
Yang et al., no radiation 35/38 8 65% 500 mg/m2 0%
Hagleitner, this study 22/80 15 40% 500 mg/m2 0%
Patino-Garcia, this study 18/34 12 55.3% 500 mg/m2 0%
*data of total group as published by Yang et al.
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Discuss ion
Although, the results of Ross and colleagues investigating the influence of variants in TPMT 
and COMT were very promising, the outcome of more recent studies argues against the 
premise that these variants might help to identify patients at risk for ototoxicity. In the 
present study, therefore, we aimed to gain a clearer picture on the role of these variants 
by adding additional data on the subjects, and by performing a meta-analysis including 
two new cohorts. 
Our Dutch dataset of 110 uniformly treated patients with osteosarcoma, is a homogenous 
group without potentially confounding factors such as cranial radiation and concomitant 
medication. For classification of cisplatin-induced hearing loss, we preferred to use the 
SIOP Boston scale as it combines the two main types of measuring ototoxicity, namely 
changes of hearing from baseline as well as absolute hearing levels10. As previously pub-
lished studies used the CTCAE criteria for the classification of ototoxicity, we reclassified 
our data according to the CTCAE criteria, and excluded grade 1 ototoxicity to better distin-
guish between cases and controls. In the Dutch cohort, and also the other newly analyzed 
Spanish cohort, we did not observe any statistically significant association between the 
genetic variants in TPMT, COMT and ototoxicity. We did observe differences between the 
two cohorts such as lower ototoxicity rate in the Dutch cohort which might be explained by 
the inclusion of adults until the age of 40 years. It is known that young children are more 
susceptible to ototoxicity from cisplatin3. Furthermore, the Dutch cohort included patients 
who have already died. It might be that controls that died have become cases if they have 
survived longer. However, the median follow up time of these patients who have died was 
2.3 years with a range between 1.1 and 5.5 years. Studies included in this meta-analysis 
showed universally that the majority of ototoxicity occurred between 0.5 and 6 months 
from start of cisplatin chemotherapy6-8.
After meta-analyses of the genetic variants in TPMT and COMT including in total 664 pa-
tients only rs4646316 variant in the COMT gene remained statistically significant. However, 
the effect was much smaller than reported in previously published studies. In the initial 
discovery cohort of Ross and colleagues the OR of this variant to develop ototoxicity was 
2.5 (95% CI: 1.5-4.3)6. Whereas the combined effect of all studies included in the me-
ta-analysis showed an OR of 1.52 (95% CI: 1.16-1.99). Three of the cohorts (excluding the 
initial study by Ross et al.) showed the same direction of effect for rs4646316, however, 
this was not statistically significant. The COMT gene encodes for the COMT enzyme which 
is involved in the inactivation of catecholamine neurotransmitters. Although, it has been 
shown that it is also highly expressed in sensory hair cells of the inner ear, its role regard-
ing auditory function remains unclear12. In addition, the influence of the variant rs4646361 
on the COMT enzyme has not been studied yet. 
Generally, the association between TPMT variants and cisplatin ototoxicity was unexpect-
ed9, as it was not previously linked to cisplatin metabolism. Recent published data support 
the hypothesis that TPMT might have an influence on cisplatin metabolism by increasing 
Figure II. Forest plots of genetic variants in COMT gene
COMT rs4646316
Odds Ratio
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI
Ross, 2009, discovery 53 66 25 40 7.3% 2.45 [1.01, 5.91]
Ross, 2009, replication 123 146 49 72 12.4% 2.51 [1.29, 4.89]
Pussegoda, 2013 141 174 104 136 26.5% 1.31 [0.76, 2.27]
Yang, 2013, radiation 208 262 92 18 30.5% 1.51 [0.93, 2.46]
Yang, 2013, no radiation 55 70 5 6 2.4% 0.73 [0.08, 6.76]
Hagleitner, this study, Dutch 32 40 87 102 11.7% 0.69 [0.27, 1.78]
Hagleitner, this study, Spanish 21 34 19 30 9.2% 0.94 [0.34, 2.58]
Total (95% CI) 792 514 100.0% 1.48 [1.13, 1.95]
Total events 633 381
Heterogeneity: Chi2=7.50, df=6 (P=0.28); I2=20% 
Test for overall effect: Z=2.83 (P=0.005) No ototoxicity Ototoxicity
COMT rs9332377
Odds Ratio
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI
Ross, 2009, discovery 14 66 2 40 10.4% 5.12 [1.10, 23.85]
Ross, 2009, replication 22 146 2 72 10.9% 6.21 [1.42, 27.19]
Pussegoda, 2013 38 174 23 136 20.6% 1.37 [0.77, 2.44]
Yang, 2013, radiation 48 260 21 128 20.7% 1.15 [0.66, 2.03]
Yang, 2013, no radiation 9 70 2 6 8.3% 0.30 [0.05, 1.85]
Hagleitner, this study, Dutch 10 44 28 116 17.6% 0.92 [0.41, 2.11]
Hagleitner, this study, Spanish 3 36 10 30 11.5% 0.18 [0.04, 0.74]
Total (95% CI) 796 528 100.0% 1.16 [0.61, 2.23]
Total events 144 88
Heterogeneity: Tau2=0.45; Chi2=18.12, df=6 (P=0.006); I2=67% 
Test for overall effect: Z=0.45 (P=0.65) No ototoxicity Ototoxicity
M-H, Random, 95% CI
Experimental Control
Odds Ratio
M-H, Random, 95% CI
Odds Ratio
Experimental Control
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protocols, the youngest population in this meta-analysis with different follow-up time be-
tween cases (5 years follow-up) and controls (2 years follow-up). The radiation cohort of 
Yang et al patients received highly ototoxic cranial irradiation, but 90% also received an 
otoprotectant, and overall these patients received a significantly lower cumulative dose of 
cisplatin. Thus, the weight attributed to a study may affect the results of the meta-analy-
sis, however this is something that cannot be circumvented in this type of analysis.  
Nevertheless, younger age and higher cumulative doses of cisplatin appear to be the most 
consistent risk factors for ototoxicity. However, an upfront risk stratification based on these 
two factors is unreliable as these factors seem to be protocol specific and dose adjustments 
may jeopardize treatment efficacy of cisplatin. The addition of otoprotective agents in com-
bination with cisplatin might be an alternative treatment strategy to prevent hearing loss. 
Although, the mechanism of cisplatin-induced hearing loss is not fully understood, several 
preclinical studies have shown that in the cochlear cells cisplatin induces the production of 
toxic levels of reactive oxygen species (ROS) which can initiate cochlear cell death leading 
to hearing loss16,17. Numerous studies have investigated a variety of antioxidant agents to 
protect cochlea cells from cisplatin damage. Among them, sodium thiosulfate, D- or L-me-
thionine, glutathione ester and amifostine were successfully tested in animal models18,19. 
The efficacy of otoprotective agents in patients is however disappointing. For instance, 
sodium thiosulfate showed an unwanted compromised antitumor effect of cisplatin20 and 
no otoprotection was observed in children with germ cell tumors treated with amifostine in 
combination with cisplatin21. 
It remains challenging to find the right balance to maintain antitumor effect of cis-
platin and on the other hand to prevent unwanted adverse effects. Innovative stud-
ies translating basic science into clinical practice are needed to unravel both, the 
mechanism of cisplatin-induced hearing loss and identification of patients at risk 
to develop ototoxicity. Pharmacogenetics may help to find new target genes, un-
fortunately it seems that the genes TPMT and COMT play only a minor role in cisplatin- 
induced ototoxicity and should therefore not guide clinical decision making 
for cisplatin dosing.
 
levels of S-adenosylmethionine (SAM)13. Furthermore, a recent study demonstrated that 
functional TPMT variants were associated with progression-free survival in cisplatin-based 
chemotherapy outcomes in ovarian cancer14. However, in vivo studies in mice with different 
TPMT genotypes showed no differences in hearing damage between TPMT wild-type and 
knockout mice8.
With the largest meta-analysis performed to date we show that the influence of TPMT and 
COMT on the development of cisplatin-induced hearing loss may be less pronounced than 
previously suggested. This lack of association observed might be attributable to heteroge-
neity between the different studies as shown in Table II. First, different patient populations 
with different ethnicities were used in the studies which could account for the differences 
in the genetic associations in the meta-analysis. Second, in the study cohorts with clear 
positive association, a heterogeneous group of patients with respectively 9 and 12 different 
types of cancers was included6,7. As a consequence, patients were treated with different 
treatment regimens sometimes including cranial irradiation and different co-medication. 
In these studies an analysis for specific patient subgroups was not performed probably 
due to the limited number of patients included for each subgroup. Also the cohorts with 
clear negative association included patients with different cancer types, one study included 
patients with osteosarcoma (this study) as in the study of Yang et al. patients with medul-
loblastoma have been included which necessitates highly different treatment protocols re-
garding cumulative dose of cisplatin, cranial radiation and concomitant medication. Third, 
the different types of cancer were not equally distributed among patients with and without 
ototoxicity, for example in the cohort of solid tumors investigated by Yang and colleagues 
35 of the 38 patients8 were reported to have hearing loss which may lead to selection 
bias. Fourth, the median cumulative doses of cisplatin ranged from 300 to 500 mg/m2 
in the different studies. However, neither in the study cohort of medulloblastomas with 
a relatively low cumulative dose of cisplatin8 nor in osteo sarcoma patients treated with 
higher doses of cisplatin (this study), an association was found.  In addition, young age 
has recently been pointed out as an important factor to develop cisplatin-induced hearing 
loss3, which may be the reason for the lower incidence of ototoxicity in the osteosarcoma 
cohort as the median age at diagnosis is older compared to the other cohorts. At last, the 
use of otoprotective agents, such as amifostine, may be a potentially confounding factor. 
A Cochrane study on this topic was due to methodological limitations of individual studies 
unable to show evidence of effect to use amifostine as an otoprotective intervention15. 
However, there was also no evidence that it had no effect as otoprotectant. In the study of 
Yang et al the use of amifostine was linked to less ototoxicity.
It is clear that all studies included in this meta-analysis have confounding variables which 
could potentially influence the development of ototoxicity. This is important given the in-
verse method of weighing studies which has been used in this meta-analysis. The studies 
of Pussegoda et al and Yang et al were consistently attributed the highest weighting. 
Pussegoda et al included a diverse population of different cancers with different treatment 
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In t roduct ion
In the past decades, progression free survival (PFS) rates of patients with osteosarco-
ma have reached a plateau1. This is in contrast to other forms of cancer, where clear 
progress has been made, either by the use of new drugs or the ability of risk strati-
fication and subsequently treatment adjustments2. Before the introduction of multi-
agent chemotherapy in the 1970s, when surgery was the only treatment, approximate-
ly 20% of the osteosarcoma patients survived3. Nowadays, cure rate for non-metastatic 
osteosarcoma patients approaches 55-65%4. Several factors influence the outcome of pa-
tients with osteosarcoma. While factors such as site and size of the tumor, age at diagnosis, 
surgical approach and response of the tumor to pre-operative chemotherapy were shown 
to be important, only metastatic status at diagnosis is a consistent negative prognostic fac-
tor5,6. The absence of more reliable predictive factors at diagnosis has resulted in uniform 
chemotherapy schedules for all osteosarcoma patients. Being able to predict individual 
treatment response before start of treatment is however crucial to define new or alterna-
tive strategies in order to improve outcome. 
Pharmacogenetics might help deliver this a priori knowledge, as has been shown for pa-
tients with colorectal cancer, acute lymphoblastic leukemia and other cancer types7,8. Al-
though a number of studies have been performed into the role of genetic variants asso-
ciated with the response to treatment in osteosarcoma patients9-11, none of these studies 
involved a comprehensive list of genes  involved in the metabolism of cisplatin and doxo-
rubicin, the two main drugs used in treatment of osteosarcoma patients. Hence, we inves-
tigated a set of genetic variants in 54 genes known to be involved in the metabolism of 
these drugs using a pathway-based genetic analysis. Subsequently, the role of the genetic 
variants in relationship to histological response and PFS was analyzed, demonstrating that 
it may be possible to define high risk groups for relapse on the basis of genetic variations 
in drug metabolizing pathways. 
Abs t rac t
Background 
Overall survival in patients with osteosarcoma is only 60%. Poor response to chemothera-
py is the dominant risk factor for poor survival. Pharmacogenetic research can offer possi-
bilities to optimize treatment and improve outcome. We applied a pathway-based approach 
to evaluate the cumulative effect of genes involved in the metabolism of cisplatin and 
doxorubicin in relationship to clinical outcome.
Methods
In the discovery group we included 126 patients with osteosarcoma. To comprehensively 
assess common genetic variation in the 54 genes selected, linkage disequilibrium (LD, 
r2=0.8) based tag-single nucleotide polymorphisms (SNP) strategy was used. A final set 
of 384 SNPs was typed using Illumina Beadarray platform. SNPs significantly associated 
with 5-year progression free survival (PFS) were replicated in another 64 patients with 
osteosarcoma. 
Resu l ts 
We identified five variants in FasL, MSH2, CASP3, ABCC5 and CYP3A4 that were associated 
with 5-year PFS. Risk stratification based on the combined effects of the risk alleles showed 
a significant improvement of 5-year PFS. Patients that carried  no or only one risk allele 
had a 5-year PFS of 100% compared to a 5-year PFS of 84.4% for carriers of 2 or 3 risk 
alleles, 66.7% PFS if a patient carried  4-5 alleles and a 5-years PFS of 41.8% for patients 
with >5 risk alleles (p<0.001).
Conc lus ion
We identified several genes that showed association with PFS in patients with osteosar-
coma. These pharmacogenetic risk factors might be useful to predict treatment outcome 
and to stratify patients immediately after diagnosis and offer the possibility to improve 
treatment and outcome.
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Se lec t ion  o f  SNPs  and genotyp ing
Literature (NCBI (PubMed, Gene)) and the Pharmacogenomics Knowledge Base 
(www.pharmgkb.org) were searched to select representative candidate genes in-
volved in pathways relevant to cisplatin and doxorubicin. In the 54 selected genes 
we investigated SNPs that have been previously associated with functional chang-
es. In addition, selected genes were covered with 5-10 tag SNPs to analyze the com-
plete gene with a minimal set of SNPs. Tag SNP selection was performed in Haploview 
(LD statistic r2 > = 0.8, minor allele frequency >0.05) using data from the Hap-
Map project (International HapMap Consortium 2007, HapMap Data Rel24/phaseII 
Nov08). A final set of 381 SNPs was selected for analysis using the Illumina Beadar-
rayTM platform (Illumina, Inc., San Diego, CA). Illumina Genome Studio software was 
used for automated genotype clustering and calling. Samples and SNPs with genotyp-
ing call rates of <85% were excluded from analyses, as well as SNPs deviating from 
Hardy–Weinberg equilibrium (p-value >0.05).
Stat i s t i ca l  ana lyses
Statistical differences between the demographic data of the discovery and replication co-
hort were assessed by the Pearson-chi square test. Two-sided p-values are considered 
statistically significant if <0.05. No multiple testing correction has been applied due to the 
exploratory nature of the analysis. 5-year PFS was defined as the interval between diagno-
sis and disease progression/recurrence (=event) and was estimated using the Kaplan-Mei-
er method. Patients without disease recurrence at the date of last follow-up were censored 
at that date. Histologic treatment response was defined as good responders with <10% 
vital cells after pre-operative therapy with two cycles of each drug. Associations between 
potential confounders (gender, age at diagnosis, metastasis at diagnosis, axial location, 
MTX as co-medication and histologic response) and DFS or histologic response were evalu-
ated using Cox’s proportional hazard regression analysis or a 2x2 table, respectively. These 
statistical analyses were performed using SPSS version 20.0 (SPSS Inc., Chicago, Ill). 
To assess the effect of a genetic variant on PFS and histologic response data were di-
chotomized in event/no event and good/bad responders, respectively. Multivariate logistic 
regression analyses of PFS and histologic response included MTX exposure (yes/no) in 
PLINK14 using the command-logistic. A meta-analysis of the discovery and replication co-
hort was performed for the statistically significantly associated variants (p<0.05) in the 
discovery cohort to investigate possible improved association signals.  For SNPs with a low 
heterogeneity fixed effects p-values and for SNPs with a high heterogeneity the random 
effects p-value are reported. 
To assess the effect of a combination of variants on PFS, a genetic risk score was composed 
as described in literature15. The score was constructed based on the number of unfavor-
able alleles (0-1, 2-3, 4-5 or >5 risk alleles) that were carried by each patient for each 
Pa t ients  and Methods
Study des ign
We used a two-stage design. In the discovery stage, we genotyped single nucleotide poly-
morphisms (SNPs) in genes that encode drug-metabolizing enzymes in the cisplatin and 
doxorubicin pathway and investigated if these variants were associated with  histologic 
response to neoadjuvant chemotherapy as well as 5-year PFS. In the second stage, SNPs 
demonstrating evidence of association in stage one were genotyped in an independent 
replication cohort subsequently a meta-analysis of the two datasets was performed. 
Pat ients
In the discovery group, 126 patients with osteosarcoma treated in two different cen-
ters (Radboud university medical center and University Medical Center Groningen, The 
Netherlands) were included. The replication cohort consisted of 64 osteosarcoma pa-
tients treated at Leiden University Medical Center, The Netherlands. All patients were 
newly diagnosed, high-grade osteosarcoma with primary localization and/or meta-
static disease and were consecutively treated between 1979 and 2008. The study was 
approved by the ethics committee of the Radboud university medical center as the 
central committee for this study. With respect to chemotherapy protocols, two dif-
ferent regimens were used. In one center of the discovery group (Radboud university 
medical center), patients diagnosed until 2002 were treated according to an institu-
tional standard therapy consisting of a maximum cumulative cisplatin (600 mg/m2) 
and doxorubicine (450 mg/m2). After 2002 and in the other two centers (University Medical 
Center Groningen and Leiden University Medical Center) patients were treated according to 
the standard schedule as given in the EURAMOS study which basically consisted of cispla-
tin (480 mg/m2)/doxorubicin (450 mg/m2) and additionally high-dose MTX (96-144 g/m2, 
according to age)12. Clinical data were collected retrospectively. 
In patients alive, DNA was extracted from blood using the QIAamp DNA Blood Midi kit 
(Qiagen, Venlo, The Netherlands) or saliva (Oragene saliva collection kit; DNA Genotek, 
Kanata, Ontario, Canada) according to the protocol of the manufacturers. From patients 
who had died, DNA of paraffin-embedded samples was extracted as recently described13.
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Figure I. Flow chart of association analyses
In the discovery group, 7 SNPs with genotyping call rates <85%, 31 SNPs deviating from 
Hardy-Weinberg equilibrium and 111 SNPs with an allele frequency <0.05 in the study pop-
ulation were excluded. In the discovery group, a total of 14 SNPs demonstrated a statisti-
cally significant association (p<0.05) with histologic response (Supplementary Table I). Of 
these, four SNPs (rs11190291, rs723456, rs4645983, rs207455) were excluded because 
of the SNPs associated with PFS. With the risk alleles of each patient we analyzed 5-year 
PFS curves using the Kaplan-Meier method. The added value of the genetic risk score was 
evaluated to predict 5-year PFS in addition to metastases at diagnose. 
Resu l ts
Pat ients
In total, we included 190 patients with newly diagnosed osteosarcoma. Patient character-
istics are depicted in Table I. Baseline characteristics did not show statistically significant 
differences between the discovery and replication groups. 
Table I. Demographic data
 Total (N=190) Discovery (N=126) Replication (N=64) p-value1
Median age (years; median) 16.9 (2.8-67.3) 15.6 (2.8-39.5) 18.2 (5.0-67.3) 0.5
Male gender (N; %) 99 (52.1%)  67 (53.2%) 32 (50%) 0.68
Primary metastases (N; %) 39 (20.5%) 26 (20.6%) 13 (20.3%) 0.96
Tumor in axial skeleton (N; %) 13 (6.8%) 9 (7.1%) 4 (6.2%) 0.36
Bad histologic response (N; %) 112 (66.3%) 77 (71.3%) 35 (57.4%) 0.07
5-year PFS2 60.50% 57.90% 65.60% 0.43
1comparing discovery vs. replication group
2patients available for analyse: Total cohort: N=115. Disovery: N=73. Replication: N=42.
The number of patients with good histologic response was slightly higher in the replica-
tion group (p=0.07). This might partially be explained by different treatment schedules 
as patients treated additionally with MTX had a slightly but not significantly better 5-year 
PFS (66.7% vs. 54.5%, p=0.13). Achieving a good histologic response was not influenced 
by any of the baseline characteristics. No difference in 5-year PFS was seen comparing 
patients with good histologic response to bad responders (61.3% vs. 55.8%, p=0.36). 
In contrast, 5-year PFS was significantly associated with co-treatment of high-dose MTX. 
Therefore, MTX exposure was used as covariate in all multivariate analyses. No confound-
ing factor was found for histologic response. 
Associat ion analyses of histologic response
In total, 177 samples (93.2%) were genotyped successfully on the Illumina Bead Array 
system, 120 patients (95.2%) in the discovery group and 57 patients (89%) in the repli-
cation group (Figure I: flow chart). 
 
126 patients with osteosarcoma: 
    6 samples  excluded with genotype rate < 80% 
381 SNPs genotyped: 
    7 SNPs excluded due to low genotype rate (<85%) 
  31 SNPs failed to meet Hardy-Weinberg equilibrium (HWE) 
111 SNPs excluded with allele frequency < 0.05 
232 SNPs in 120 patients remained for further analyses 
SNPs with p < 0.05 
Histologic response:   14 SNPs 
5-year PFS:    23 SNPs  
14 SNPs with improved p-value for histologic response 
  4 SNPs excluded due to low genotype rate (<85%) 
 
23 SNPs with improved p-value for 5-year DFS 
  9 SNPs exluded due to low genotype rate (<85%) 
Meta analyses: 
Histologic response:  No SNP associated 
5-year PFS:   5 SNPs 
64 patients with osteosarcoma: 
  7 samples excluded with <80% genotype rate 
Discovery 
Replication 
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Figure II. 5-year PFS based on genetic risk score
Adding the genetic risk score to the presence of metastases at diagnosis, the most import-
ant conventional risk factor, significantly improved the ability to predict PFS. The 5-year 
PFS of patients without metastases at diagnosis showed a similar effect with a survival 
of 100% in patients carrying no or one risk allele compared to a 5-year PFS of 85% in 
patients with 2-3 risk alleles, 69.8% with 4-5 risk alleles and 53.8% in patients with 
>5 risk alleles (p=0.008). In patients with metastases at diagnosis, all patients were 
carriers of at least 2 risk alleles, meaning there were no patients with no or one risk 
allele in this subgroup. The 5-year PFS of patients with 2-3 risk alleles and metastases 
at diagnosis was still 80%. However, survival decreased to 56.2% in patients carrying 
4-5 risk alleles and only 12.5% in patients with >5 risk alleles (p=0.007; Figure III). 
of low genotyping rates in the replication cohort. Meta-analyses of the remaining 10 SNPs, 
demonstrated 2 statistically significant associations (rs3136326 and rs1800936) however 
no improved association signal of the discovery and replication cohorts compared to the 
discovery cohort alone was seen (Supplementary Table I). 
Assoc ia t ion  ana lyses  o f  5-year  PFS
Multivariate linear regression analyses corrected for high-dose MTX resulted in the identi-
fication of 23 SNPs that demonstrated a statistically significant (p<0.05) association with 
5-year PFS, in the discovery group. Of these 23 SNPs, nine SNPs (rs3181345, rs4647616, 
rs1233398, rs2808676, rs3176646, rs2917669, rs1805324, rs1296500, rs1895419) 
showed low call rates for the replication cohort, leaving 14 SNPs for analysis (Supple-
mentary Table II). Five SNPs (rs763110, rs4638843, rs939338, rs2720376, rs4646437) 
demonstrated an improved association signal with PFS in the meta-analysis of the discov-
ery and replication cohorts compared to the discovery cohort (Table II). These SNPs were 
not associated with histologic response. 
Table II. Genetic variants associated with 5-years PFS
    Discovery group Meta analyze fixed effects
Gene SNP Allele  P OR 95% CI P OR 95% CI
FasL rs763110 T 5’UTR 0.04 1.97 1.04-3.73 0.02 1.76 1.08-2.87
MSH2 rs4638843 C Intron 0.04 2.32 1.02-5.27 0.007 2.66 1.31-5.36
ABCC5 rs939338 G Intron 0.03 1.86 1.06-3.24 0.03 1.67 1.06-2.63
CASP3 rs2720376 G Intron 0.02 0.52 0.30-0.90 0.01 0.57 0.36-0.89
CYP3A4 rs4646437 A Intron 0.02 0.34 0.13-0.85 0.02 0.43 0.21-0.88
Multivariate linear regression analyses corrected for high-dose MTX
Genet i c  r i sk  score 
Our genetic risk score for PFS was calculated based on the five statistically significantly 
associated SNPs (rs763110, rs4638843, rs939338, rs2720376, rs4646437) in the me-
ta-analysis of this study. Thus, the potential genotype score for each patient could range 
between 0 and 10. Since only a small number of patients had a score of 6 or higher, we 
merged these groups into one group for analysis, resulting into a total of four groups for 
the final analyses representing 0-1, 2-3, 4-5 or more than 5 unfavorable alleles. 
After adjusting for treatment with MTX, which was the only confounding factor for PFS in 
this study-group, we found that the genetic risk score was associated with 5-year PFS. 
Patients without or one risk allele showed a survival of 100% compared to a 5-year PFS 
of 84.4% with 2-3 risk alleles, 66.7% with 4-5 alleles and 41.8% with >5 risk alleles 
(p<0.001, Figure II). 
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C, member 5 (ABCC5) and Cytochrome P450 3A4 (CYP3A4) to be associated with PFS. 
The minor allele of the variants in FasL, MSH2 and ABCC5 were associated with a lower 
survival, the minor allele of the other two SNPs were associated with a better survival 
(Supplementary Table II). 
FasL induces apoptosis and appears to have a role in the development and progression of 
cancer, such as breast cancer17. The associated SNP, rs763110 (844T>C) of the FasL gene, 
is suggested to influence FASL expression18. It has been demonstrated that Fas expres-
sion correlates inversely with metastatic potential in human osteosarcoma cells.19 This is 
in accordance with our findings where the T allele, linked to a low expression of FasL, is 
associated with unfavorable disease outcome. 
Contradictory results are shown with respect to the variant rs4638843 in the MSH2 gene. 
In our study this variant was negatively associated with PFS while the same variant was 
shown to be positively associated with survival in colorectal cancer20. The MSH2 gene 
encodes for the MSH2 protein which is part of the MutSα complex in the Mismatch Repair 
(MMR) system. This system recognizes specific types of DNA damage, as caused by cis-
platin.
Another pharmacogenetic association found in our study represents a variant in CASP3 
which is one of the main executor genes in cell apoptosis. Association studies are scarce 
but, as CASP3 is at the heart of the apoptotic process it is reasonable to hypothesize that 
genetic variations in this gene have an influence on outcome. 
In the present study we also identified a variant in ABCC5 to be associated with an un-
favorable 5-year PFS. It has been demonstrated that elevated expression of ABCC5 (or 
MRP5) confers resistance to cisplatin and doxorubicin in different cell lines21. Additionally, it 
was shown that ABCC5 supports osteoclast formation promoting the occurrence of breast 
cancer metastasis to the bone22. 
The last association identified was with a variant in CYP3A4 which is involved in oxidation of 
cisplatin but also plays a role in the doxorubicin pathway. In osteosarcoma tumors, expres-
sion of CYP3A4 was found to be significantly higher in the primary tumor of patients who 
developed distant metastatic disease compared to patients with progression free survival23.
 
This pharmacogenetic analysis is the first in literature to report on a combined effect of genetic 
variants using a genotype risk score in osteo sarcoma patients. To evaluate our findings we 
added conventional risk factors, such as metastases at diagnosis to the current SNP panel. 
Interestingly, in both patients with or without metastases at diagnosis we were able to dis-
tinguish patients with good outcome from patients with poor outcome based on the genetic 
risk score. The concept of combining metastatic status and genetic profile may be used to 
refine future protocols. We were able to identify a group of patients with very poor out-
come which may benefit from alternative or novel treatment strategies. Our findings could 
have important implications for treatment and management of osteosarcoma and deserve 
validation in a larger, prospective cohort. Although the results of our study are promising, 
Figure III. 5-year PFS based on genetic risk score, analysis split based on the presence 
of metastases at diagnosis
 
 survival of patients without metastases                 survival of patients with metastases
 
D i scuss ion
In this study we showed that the pharmacogenetic profiles of patients with osteosarcoma 
may be used to stratify patients into good and bad responders. Based on our analysis five 
genetic variants were significantly associated with 5-year PFS. To our knowledge this is the 
first pharmacogenetic study in osteosarcoma patients that demonstrate that it is possible 
to perform risk stratification at start of treatment for this specific patient group. Interest-
ingly, histological response which is still the predominant factor for survival in many studies 
was not associated with 5-year PFS in this study. We are not the first to indicate that the 
value of histological response for treatment stratification might be limited. Several study 
trails have shown that intensification of chemotherapy preoperative resulted in a significant 
higher proportion of good responders, but outcome was similar16. Nevertheless, we investi-
gated whether germline genetic polymorphisms can predict histologic response to pre-op-
erative treatment. Although some associations where found in the discovery group, none 
of the identified SNPs showed an improved signal in the meta-analysis of both cohorts. Two 
of the associated SNPs remained significant though with higher p-values compared to the 
discovery cohort. It cannot be excluded that these SNPs represent true associations as our 
replication cohort is relatively small. Based on the preliminary results we advise that our 
findings should be validated in a larger cohort. 
We identified one functional SNP in the Fas Ligand (FasL) gene and four tag-SNPs in the 
MutS homologue 2 (MSH2); Caspase 3 (CASP3); of the ATP-binding cassette, sub-familiy 
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the number of patients included in these analyses is rather limited. Osteosarcoma is a rare 
disease and, at present, no other pharmacogenetic multidrug candidate pathway gene 
study in literature is available that includes a discovery and replication cohort as large as 
ours (n=177). Including this study, a total of four outcome-related pharmacogenetic stud-
ies in patients with osteosarcoma have been published9-11. However, different treatment 
protocols including additional agents besides cisplatin and doxorubicin resulted in different 
strategies to select genes for pharmacogenetic analyses. As a consequence, most of the 
previously reported genes were not included in this study. 
In conclusion, we identified several genes that might be associated with treatment re-
sponse in patients with osteosarcoma. Replication of our data in additional cohorts and 
prospective clinical studies is warranted to reaffirm the potential of using pharmacogenet-
ics in patients with osteo sarcoma and bring about a more personalized treatment for these 
patients.

CHAPTER 9
 
General  d iscussion
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Retrospect ive  ana lys i s  o f  our  cohor t  o f  pat ients 
w i th  os teosarcoma showed that  age  was  a  pred ic-
t i ve  fac tor  fo r  overa l l  surv iva l
Further improvements in outcome of osteosarcoma patients may depend on the develop-
ment of new agents and the refinement of the osteosarcoma therapy. Therefore, it may 
be helpful to identify biomarkers to differentiate patients into groups that will benefit more 
form a particular medicine than others. Beside the presence of metastasis at diagnose, 
there is no clear consensus regarding upfront relevant prognostic factors. In several malig-
nancies age is a well-known prognostic factor and used for risk stratification. Its relevance 
in the treatment of osteosarcoma patients is however controversial. In pharmacological 
terms, age is a very interesting factor as age-related changes in the cell (e.g. oxidative 
stress, mitochondrial dysfunction, and various genetic mechanisms) are known to affect 
pharmacological responses8. Expression changes in enzymes have not only been seen in 
the first year of life but throughout childhood and adolescence9. Therefore, we retrospec-
tively analyzed the role of age in the treatment of osteosarcoma patients as described in 
chapter 2. Beside the presence of metastases we showed that age was an independent 
prognostic factor for overall survival. Patients older than 20 years of age at time of diag-
nose had a poorer prognosis with an overall survival of 33.3% compared to young patients 
with overall survival of 70.6%. Age remained a significant prognostic factor independent 
on metastatic stage at diagnosis and tumor location. After our data were published in 
2011, the Children’s Oncology Group (COG) described the influence of age on outcome in 
osteosarcoma patients in a large cohort of their four recent prospective North American 
Cooperative Group trials, including 1054 patients. Similar to our results, they showed that 
an age above 18 years was independent of other risk factors associated with poorer event 
free survival and overall survival and herewith confirmed our findings10. Similar to previ-
ous reports, this study found pelvic site, the presence of metastatic disease at diagnosis, 
positive tumor margins and a poor histologic response to chemotherapy to be significant 
predictors of poor prognosis. 
Although, it is generally known that children are not little adults in many ways, the rele-
vance of age-dependent changes in drug metabolizing, the so called developmental phar-
macology11, has only recently been integrated into clinical decision making regarding drug 
doses. Age-related changes in body composition as well as growth and development of or-
gans like liver, kidneys and intestine influence the absorption, distribution, metabolism and 
elimination of medications throughout infancy, childhood and adolescence11. So far, studies 
regarding developmental pharmacology are scars and predominantly focused on phase I 
enzymes such as the P-450 cytochromes (CYPs). However, evidence has shown that ex-
pression levels of several isoenzymes of the CYP family12 as well as hepatic and intestinal 
drug transporters9 vary throughout childhood and as such may influence pharmacokinetic 
of metabolized agents by these systems. For instance, the CYP3A4 expression levels ex-
Cl in i ca l  re levance,  genera l  d i scuss ion 
and fu ture  perspect ives
Osteosarcoma is the most common primary malignant bone tumor in children and ad-
olescents. Although outcome improved after the introduction of multi-agent che-
motherapy, survival for these patients is still poor. It appears that we have reached 
the limit in the survival of osteosarcoma patients achievable with currently available 
chemotherapy. The studies performed and described in this thesis were initiated to 
study the role of pharmacogenetics in the treatment of patients with osteosarcoma. 
 
Since the 1970’s survival for patients with osteosarcoma without metastatic disease at 
presentation, remains about 60%-65%1. In case of detectable metastases at diagnosis 
overall survival is only 30%2. Thus, new approaches in first line treatment are needed 
to improve survival. Despite new diagnostic and imaging techniques over the past view 
years and considerable improvements in surgical techniques that achieve local control with 
limp-sparing procedures, this has not resulted in improved overall survival. In addition, 
very little changes have been seen as far as systemic treatment concerns. Drugs such as 
interferon3 and monoclonal antibodies4 have been trialed in preclinical and clinical studies 
but showed no improvement in event free survival. 
With the advances in sequencing technologies such as used in pharmacogenetic studies, 
metabolic pathways which can affect individual responses to drugs, can be studied. A bet-
ter knowledge of the mechanisms responsible for response to current chemotherapeutic 
regimens may lead to the development of more effective approaches in the treatment of 
patients with osteosarcoma. Pharmacogenetic research studies the influence of inherited 
genetic variants associated with treatment response. These genetic variants can be evalu-
ated for their pharmacokinetic and pharmacodynamic effects on relevant drugs in individ-
ual patients. One of the classical models concerning pharmacogenetics in oncology is the 
implementation of thiopurine methyltransferase (TPMT) genotype tests in the treatment 
of several non-malignant and malignant disorders with thiopurines such as mercaptopu-
rine5. Genetic variability in the TPMT gene has been associated with differing levels of 
TPMT leading to dose adaptations of mercaptopurine6. Similarly, a dose recommendation is 
available for the treatment of patients with 5-fluorouracil as dihydropyrimidine dehydroge-
nase (DPYD) deficiency has been linked to sever toxicity7. The perception that part of this 
interpatient variability is inherited, and therefore predictable, may be applied in the de-
velopment of personalized medicine. If pharmacogenetic research contributes to a better 
understanding of the mechanism of drug response in these patients, it may offer possibil-
ities to individualize treatment and improve outcome and perhaps, even reduce toxicities. 
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patients that are still alive several years after diagnosis. We compared freshly isolated DNA 
from blood with DNA from archived material from the same patient. Our results indicated 
that 100% of samples (N=18) had complete concordance for all genetic variants examined 
and confirmed that the processing and storage of DNA is not affecting the results. 
Applying this procedure provides a new opportunity to analyze samples that have been 
preserved on FFPE. However, there is concern that DNA derived from FFPE tissues might 
be of limited value as it may not adequately represent the genetic data obtained from 
germline DNA. With us, other studies have addressed this this issue14,15. These studies 
consistently show that concordance between germline and FFPE material is virtually 100%. 
In cancers like osteosarcoma with an incidence of 3-4 new cases per million per year, 
prospective studies are often too time consuming. With isolation of DNA from historical 
material it is possible to undertake comprehensive studies in much larger cohorts which 
is essential for pharmacogenetic research. Furthermore, many current clinical trials and 
hopefully all future clinical trials will archive patient’s molecular information making these 
data accessible for future generations of genetic research. 
Cand idate-gene ana lys i s :  Genet i c  var iants  may 
in f luence  methot rexate  p lasma concent ra t ions  in 
ped ia t r i c  ma l ignanc ies
In chapter 5, we performed a candidate-gene analysis to study the association of ge-
netic variants with the elimination of MTX. The results of our study of 41 variants in 20 
MTX-related genes showed two polymorphisms, ABCC2 3972C>T and AMPD1 c.34C>T, to 
be suggestively associated with an increased elimination of MTX 48 hours after infusion 
and a lower risk to develop high grade toxicity. A recently published study in 151 patients 
with ALL confirmed our findings regarding ABCC2 3972C>T. Lopez-Lopez and colleagues 
showed several SNPs in the ABCC2 and ABCC4 gene to be statistical significantly asso-
ciated with MTX clearance and different toxicity parameters16. Patients with the CT/TT 
genotype of the ABCC2 3972C>T polymorphism showed lower MTX plasma concentra-
tions at 72 hours after infusion compared to the CC genotype (MTX concentration <0.2 
umol/l: 71.6% of CT/TT genotype vs. 50% of CC genotype; OR=0.40, 95% CI: 0.18-0.86, 
p=0.018). Furthermore, a haplotype in ABCC2 including the ABCC2 3972C>T polymor-
phism showed the same effect on MTX toxicity as in our study. Therefore, the ABCC2 poly-
morphism seems to play a role in the metabolism of MTX. 
Several choices have been made regarding the method of this exploratory 
study. First, we focused on candidate genes and polymorphisms that are likely to have 
a direct impact on the function of the gene as to increase our power to identify relevant 
variants. Second, we optimized our power by including all t=48 hours MTX plasma levels 
after each course of each patient whereas others included only the highest score during 
ceed adult levels in the first years of infancy12, e.g. the clearance of carbamazepine from 
plasma, which is metabolized by CYP3A4, is greater in children compared to adults13. This 
example shows that factors that cause variation in drug responses are complex involving 
genetic, environmental and physiological factors, like age. 
Ana lys i s  o f  ped ia t r i c  os teosarcoma pat ients 
showed no s ign i f i cant  d i f fe rences  regard ing  t reat-
ment  s t ra teg ies  over  the  past  three  decades
In the Netherlands, approximately 35-45 new patients with osteosarcoma are diagnosed 
each year which makes this tumor a rare disease. For our genetic analyses we includ-
ed patients treated up to 30 years ago. For possible confounding factors, we studied in 
chapter 3 survival trends in our pediatric population of 130 children who were treated be-
tween 1979 and 2008. We found an improved survival in the patients treated in the last de-
cade which was unexplained. In fact, since the 1970’s treatment trials contained the same 
three-drug backbone consisting of cisplatin, doxorubicin and high-dose MTX. Furthermore, 
our study showed no significant changes in drug doses or patients’ characteristics in the 
past three decades. As the basic treatment options have hardly changed since the 1970s 
we suggest that the slight improvement which is seen in the last decade might be attribut-
able to evolving factors such as better supportive care. 
Since patients today still receive exactly the same drugs as they would have 30 years ago, 
we were able to enlarge our dataset for the pharmacogenetic analyses. However, even 
more importantly, our analysis illustrates the stagnation of treatment opportunities and 
therefore improvement in survival of patients with osteosarcoma.
 
A new method was  deve loped to  use  h i s tor i ca l , 
para f f in  embedded mater ia l  fo r  pharmacogenet i c 
s tud ies
For our pharmacogenetic studies, we included data from patients treated between 1979 
and 2008 of which approximately 50% had already died. Obviously, from these patients 
freshly isolated DNA was not available, but archived tumor and surrounding normal tissue 
from these patients is still stored at our department. To be able to analyze DNA of patients 
alive and patients that died, e.g. to prevent biased analysis of missing patients, we devel-
oped a method to obtain germline DNA from archived formalin-fixed paraffin-embedded 
(FFPE) tissues of patients that have died as described in chapter 4. Using this modified 
protocol, we were able to obtain adequate DNA in decalcified FFPE tissue suggesting that 
with this adaptation, DNA can be successfully recovered from decalcified archived tissue in 
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Our  rep l i ca t ion  s tudy fa i l ed  to  reproduce  f ind ings 
o f  an  assoc ia t ion  between TPMT  o r  COMT  gene and 
oto tox ic i ty
In the study presented in chapter 7 we tried to replicate the promising data of Ross and 
colleagues who suggested an important role of TPMT and COMT in the development of cis-
platin-induced ototoxicity27. Ross and colleagues identified patients at risk for cisplatin-in-
duced ototoxicity and suggested that according to their genotype, these patients could be 
offered less toxic alternative therapy. Based solely on this specific study the US Food and 
Drug Administration has changed the cisplatin label to indicate the association of TPMT with 
ototoxicity28. These data were recently successfully replicated in an independent cohort by 
the same research group29. However, we could not replicate these data. Our findings are 
in concordance to the replication study of the St. Judes research group30 that also could 
not confirm the association between TPMT, COMT and ototoxicity. The results of our group 
and of the St Judes research group versus those of Ross and colleagues are contradictive. 
Differences between the initial study, our own study and the two replication studies may 
be caused by genetic but also non-genetic factors, such as different treatment regimens 
that can be highly variable in a clinical setting. We investigated a far more homogenous 
cohort compared to the initial study by Ross27, without potentially confounding factors such 
as cranial radiation and concomitant medication. Furthermore, the previously published 
studies were relatively low powered, with 162 patients in the initial study, 155 and 195 
patients in respectively the two other replication studies . To address this issue further, we 
performed a meta-analysis of all published results on this topic. The variant rs4646361 in 
the COMT gene was the only association which remained statistically significantly associ-
ated with the development of cisplatin-induced ototoxicity, however the effect was much 
smaller compared to the initial study. It is debatable whether this association holds in a 
large-scale study. Herewith we show that the study of Ross and colleagues represents an 
illustrative example of the vulnerability of small studies to detect false-positive findings31. 
The initial study used a panel of nearly 2000 variations capturing 220 key drug metab-
olism genes. The association between TMPT and COMT with cisplatin-induced ototoxicity 
was unexpected. First, platinum-based products are no known substrates for TPMT and 
second, only a single study has implicated COMT in sensorineuronal deafness, however the 
molecular mechanism is still unclear32. Therefore, before considering clinical application of 
a genetic test, research should be performed in well powered cohorts of well-characterized 
phenotypes and routinely include a replication cohort for validation. 
the whole treatment17,18. Finally, we gained power by including ALL patients who were also 
treated with high-dose MTX according to the ALL-10 protocol19 at our department. 
After the analyses of our data in 2008, a GWAS studying 398,699 SNPs has been pub-
lished20. This study of over 400 patients with ALL reported associations with genetic vari-
ants in the anion transporter polypeptide, SLCO1B1. This transporter has not previously 
been associated with the MTX metabolism and therefore not selected for our own study. 
In this GWAS study, the strongest association was observed with the SLCO1B1 rs4149056 
SNP. Recently, these results were replicated in two independent cohorts21,22. In both rep-
lication studies the variant rs4149056 was confirmed to be significantly associated with 
MTX kinetics. These subsequent findings illustrate the shortcomings of a candidate gene 
approach as was used in our study with potentially inadequate pre-selection of candidate 
genes. Nevertheless, our results can provide an incentive for future studies into pharmaco-
genetics of MTX in cancer, especially since identical results of the ABCC2 variant have been 
seen in the recently published study of Lopez-Lopez and colleagues16. 
Meta-ana lys i s :  The ro le  o f  the  MTHFR  677C>T 
var iant  in  methot rexate- induced l i ver  tox i c i ty  in 
pat ients  w i th  cancer 
The most widely studied genetic variant with respect to MTX metabolism is the MTHFR 
677C>T variant as it is a key enzyme for intracellular folate homeostasis and metabo-
lism.  However, contradicting results for association with MTX-induced hepatic toxicity have 
been published17,18,23,24. Analogous to published data, our univariate analyses in chapter 6 
showed indecisive results regarding the association between the variant in MTHFR and 
hepatic toxicity. Although, patients with the 677TT genotype showed a clear trend for an 
increased risk to develop hepatotoxicity, results were not statistically significant. On the 
basis of the analysis of our data on 98 MTX-treated pediatric cancer patients and the me-
ta-analysis, we concluded that in patients with cancer, the MTHFR 677T allele has a minor 
role in the development of MTX-induced hepatotoxicity.
By the time we published our results two other research groups had also investigated the 
influence of the MTHFR gene on toxicity in cancer patients by performing a meta-analysis. 
One study showed a positive association between the 677C>T variant and hepatotoxicity25, 
but similar to our results this was not confirmed in the second study by Lopez-Lopez and 
colleagues26. In our study we performed a number of subgroup analyses, in particular to 
determine whether therapy-related factors were associated to the development of hepa-
totoxicity. These subgroup analyses supported our overall findings of a minor role of the 
MTHFR 677C>T polymorphism on the development of hepatotoxicity. 
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which is shown to enhance the sensitivity of human osteosarcoma cells to agent such as 
doxorubicin by p53-dependent apoptosis38,39, and is incorporated in the phase III Euramos 
I trial. Patients with good histologic response to neoadjuvant therapy were randomized to 
continue traditional chemotherapy or receive additional IFN α. Preliminary data presented 
at ASCO 2013 congress3 showed no differences in a rather short follow-up period of 3-year 
event free survival between the arms (77% in the IFN α arm vs. 74% in the standard 
arm). It might be possible that a longer follow-up period will show more effect of IFN α, 
as the median time to relapse is approximately 3-4 years after end of treatment. Another 
immunomodulator being studied in phase II trials is muramyl tripeptide-phophatidyl eth-
anolamine (MTP-PE). First results showed improved overall survival in both patients with 
local disease and patients with metastatic disease40. Regarding bisphosphonates, positive 
results in several models of osteosarcoma cell lines lead to phase I/II trials of the bisphos-
phonate, zoledronate. Phase III trials on this agent have still to be performed. Another 
increasingly important class of anticancer therapies are monoclonal antibodies. So far, 
trastuzumab which is a monoclonal antibody to HER2 was administered in a phase II trial 
in patients whose osteosarcoma tumor overexpresses HER2. However, no statistical differ-
ence was found between the study arm and the standard arm41. There is a clear need for 
newer effective agents for patients with osteosarcoma. 
In this thesis we used a candidate- or pathway gene approach which is a hypothesis driven 
method to investigate genetic variants in genes known to be associated with the trait of 
interest e.g. metabolism of the used medication. However, this approach is limited to the 
established pharmacological pathway. Not all genes relevant for the metabolism of the 
chemotherapeutic agents might have been studied. A more extensive study involving all 
genetic variants in the entire biologic pathway will therefore be a logical next step. Tech-
niques such as the DMET (drug metabolism enzymes and transporters) enable specifically 
genetic analysis of the involvement of metabolic pathways in drug metabolism. It provides 
information concerning 1936 genetic variations in 225 genes involved in drug disposition. 
For identification of significant new biomarkers the DMET is therefore suited to understand 
more about the pharmacological response observed in patients. Another technique is a 
GWAS which is a good approach to study the entire genome in a hypothesis free manner 
to identify genes not previously known to be associated with a specific trait. Recently, 
an impressive study in the field of rheumatoid arthritis (RA) has performed a GWAS in 
more than 100.000 patients and identified target genes of approved therapies for RA and 
suggested drugs approved for other indications to be repurposed for the treatment of 
RA42. GWA studies aiming to identify predictive markers for drug efficacy end points such 
as progression-free survival however, necessitate large cohorts. Especially, when study-
ing associations between clinical outcome and genetic polymorphisms large cohorts with 
well-controlled clinical protocols are required. These GWA studies can be performed only 
through large international collaborative efforts and with extensive biobanking. Therefore, 
we recently indicated a comprehensive study investigating the influence of genetic poly-
Our  pathway-gene assoc ia t ion  s tudy shows f i r s t 
s teps  to  persona l i zed  med ic ine  in  the  t reatment 
o f  pat ients  w i th  os teosarcoma
The pharmacogenetic study described in chapter 8 investigates, to our knowledge, the 
most comprehensive set of SNPs that are involved in the metabolism of cisplatin and 
doxorubicin in patients with osteosarcoma. This pathway-gene association study of 177 pa-
tients, which is the largest cohort of patients with osteosarcoma for pharmacogenetic stud-
ies to date, showed two interesting findings. First, histologic response was not associated 
with a 5-year PFS. This finding is not completely unexpected as it has been suggested by 
others33,34. Growing evidence shows that the positive effect of a good histologic response 
regarding favorable outcome is dependent on the combination and dose of agents given in 
the neoadjuvant traject33. Moreover, histologic response cannot be assessed at the time of 
diagnose making this factor unattractive to predict survival. Second, we were the first and 
only study to develop a stratification score based on the associated genetic variants show-
ing an additive effect of unfavorable variables. In the subgroup of patients with metastases 
at diagnose the genetic risk score distinguished patients with a relatively good outcome 
to the group of patients with poor survival. The presence of metastases at diagnose is the 
most consistent prognostic factor. The ability to differentiate patients with even a worse 
outcome in this subgroup gives new opportunities in treatment strategy. These patients 
may be candidates for participation in clinical trials of new agents. 
Including our study, a total of four outcome-related pharmacogenetic studies in patients 
with osteosarcoma have been published. The research group of Caronia and colleagues35,36 
have performed two candidate gene studies identifying polymorphism in ERCC2, ABCC3 
and ABCB1 gene to be associated with osteosarcoma outcome. A pilot study of Windsor 
and colleagues37 found an association of the CCNP1 gene with outcome. Of all associated 
genes in the different studies interestingly only one variant in the ABCB1 gene (rs1128503) 
was studied by two research groups. This variant was positively associated with survival 
in the study of Caronia but showed no statistical significance in the study of Windsor and 
colleagues. Different study protocols with different combination of agents resulted in the 
variety of different genes that have been investigated so far. Hence, a pharmacogenetic 
profile for survival might as well be protocol-specific. 
Fu ture  perspect ives
It is clear from our studies and data from others, that the benefit of traditional chemo-
therapy containing cisplatin, doxorubicin and high-dose MTX has reached its limits. In par-
ticular, for patients with unfavorable outcome no alternative effective therapy is currently 
available.  In the last five years, several clinical trials of investigational agents have been 
published. One of the most promising agents is the immunomodulator interferon-α (IFN α) 
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years in this study. Therefore, other factors like empiric use of broad spectrum antibiot-
ics in case of neutropenic fever, pain management, antiemetic’s, nutrition, blood banking 
and improved pediatric intensive care might have improved the acceptance of the current 
treatment. Furthermore, we showed that late cardiac effects and second malignant neo-
plasms can become evident many years after treatment and can have profound impact on 
cancer survivors. 
Chapter 4 describes the quality control of assays and technologies applied for the isola-
tion of DNA from long-time stored, decalcified, paraffin-embedded tissue. In cancers like 
osteosarcoma with approximately 40-50% of patients who have died, archived histolog-
ical specimens are often the only accessible source of biological material. However, this 
material has been decalcified and paraffin-embedded for many years which can severely 
affect the quality of the DNA. Therefore, we developed a method to extract high quality 
DNA from stored and decalcified, formalin-fixed paraffin-embedded tissues. Subsequent 
downstream analysis showed that the obtained DNA was of sufficient quality to be used for 
the methods described in this thesis. Our downstream analysis showed 100% concordance 
between genotypes obtained from DNA of FFPE tissue and the genotypes obtained from 
DNA of blood or saliva (the normal DNA source) from the same patients. In this chapter, we 
have demonstrated that formalin fixed and paraffin embedded tissue, whether decalcified 
or not, can be used for genetic polymorphism analysis using Taqman® allelic discrimination 
assays. This forms an unique opportunity to combine new insights in genetic research with 
historical patient cohorts.
In chapter 5 we analyzed genetic variants in 20 genes involved in the metabolic pathway 
of methotrexate (MTX) in patients with osteosarcoma for their association with delayed 
MTX elimination. High-dose methotrexate (MTX) forms a cornerstone in the treatment of 
several pediatric malignancies including osteosarcoma. Delayed MTX elimination increases 
the risk of treatment associated toxicity and necessitates increased leucovorin rescue and 
additional hospitalization for hydration and urinary alkalinization. In total, 640 courses of 
high-dose MTX were evaluated. At least one episode of MTX-induced toxicity grade 3 or 4 
was recorded in 41.8% of the patients. Four polymorphisms showed an association with 
MTX plasma levels with p-value <0.10: ABCC2 c.3972C>T, AMPD1 c.34C>T, ITPA c.94C>T 
and GSTT1del. Association analyses for the four polymorphisms for MTX-induced toxicity 
(grade 3 and 4) showed however no statistically significant association. In conclusion, we 
found indications that pharmacogenetic variants affect MTX plasma levels. In contrast to 
the expectations the variants were not associated with toxicity. Nevertheless, our results 
can provide an incentive for future studies into pharmacogenetics of MTX in childhood 
cancer.  
Osteosarcomas are the most frequent bone tumors in childhood and adolescence. Although 
disease-free survival improved by the introduction of chemotherapy in the late 1970’s to 
approximately 60-70% in non-metastatic disease and 20-30% in metastatic disease, still 
50% of the patients with osteosarcoma will not survive. A poor response to chemother-
apy is the dominant risk factor for poor survival. A better knowledge of the mechanisms 
responsible for poor response and adverse events related to current chemotherapeutic 
regimens may lead to the development of more effective chemotherapeutic approaches 
and improve outcome and perhaps, even reduce toxicities. One way to improve treatment 
of the patients is at the level of pharmacogenetics which refers to genetic differences af-
fecting individual responses to drugs, both in terms of therapeutic effect as well as adverse 
effects. In this thesis the relevance of polymorphisms in genes involved in the metabolism 
of chemotherapeutics used in the treatment of patients with osteosarcomas was studied. 
Chapter 1 contains a general introduction and describes current strategies for treating 
patients with osteosarcoma, the relation between prognostic factors and survival and gives 
a short overview on the current knowledge concerning the role of pharmacogenetics in the 
treatment of cancer. 
Chapter 2 describes a retrospective analysis with the aim to analyze whether age has an 
influence on outcome. Osteosarcoma patients treated in our hospital between 1979 and 
2008 were included in this study. In total, 102 patients with primary osteosarcoma were 
included. Overall survival (OS) of the whole population was 53.5% with a 5-years dis-
ease-free survival (DSF) of 47.1%. Beside known prognostic factors, such as histological 
response and the presence of metastases, age markedly affected survival with an OS of 
70.6% in patients below 10 years of age, 52.5% in patients 11-19 years and 33.3% in 
the patient group 20-40 years (p=0.002). When analyzed as continuous variable, age was 
found to be inversely proportional related to survival (p=0.048). In conclusion, younger 
patients have a significantly better outcome than older patients.
Chapter 3 focused on trends in survival rates and long-term toxicity in pediatric patients 
with osteosarcoma. In this study, we retrospectively evaluated, whether after the introduc-
tion of neoadjuvant chemotherapy in the late seventies, further improvement in outcome 
of osteosarcoma patients was achieved. In total, 130 pediatric patients under the age of 
20 years with newly diagnosed, primary localized or metastatic high-grade osteosarcoma 
were analyzed regarding demographic, treatment-related variables, long-term toxicity and 
survival data. The overall period of 30 years was split into sub-periods relating to the major 
changes in treatment protocol (1979–1983, 1984–2002, and 2003–2008). Comparison of 
the different time periods showed that the 5-year OS improved from 58.6% for children 
diagnosed during 1979-1983 to 78.6% for those diagnosed during 2003-2008 (p=0.13). 
Interestingly, treatment agents and dosage basically remained the same over the past 30 
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In chapter 6 we investigated the role of the MTHFR c.677C>T polymorphism in MTX-in-
duced hepatotoxicity by analyzing a Dutch cohort of pediatric patients treated with high 
doses of MTX and subsequently performing a meta-analysis. Our cohort contained 98 
patients with osteosarcoma or ALL receiving 542 courses of high-dose MTX. Hepatotox-
icity was evaluated retrospectively according to common terminology criteria for adverse 
events (National Cancer Institute Criteria). The analysis showed a 1.8-fold increased risk 
for the T vs. the C allele (95% CI 1.0-3.2, p=0.04). This finding was not supported by 
the meta-analysis including seven studies and 1044 patients; the OR for the 677 T versus 
C allele was 1.1 (95% CI: 0.84–1.5, p=0.25). In conclusion, in patients with cancer, the 
THFR 677T allele has only a minor role in the development of MTX-induced hepatotoxicity. 
Chapter 7 aimed to evaluate the role of polymorphisms in the TPMT and COMT genes in 
cisplatin-induced ototoxicity as recent studies have suggested that variants in these genes 
can predict the development of cisplatin-induced hearing loss. Therefore, two independent 
cohorts of 110 Dutch and 38 Spanish patients with osteosarcoma were investigated and a 
meta-analysis was performed including all previously published studies resulting in a total 
population of 664 patients with cancer. Only, the genetic variant rs4646316 in the COMT 
gene showed a significant association with ototoxicity (OR A versus T allele = 1.5, 95% CI: 
1.14-1.97, p=0.003). However, the effect was much smaller than reported in previously 
published studies. With this largest meta-analysis performed to date, our study showed 
that the influence of TPMT and COMT on the development of cisplatin-induced hearing loss 
may be less important than previously suggested.
In chapter 8 we applied a pathway-based approach to evaluate the cumulative effect of 
genes involved in the metabolism of cisplatin and doxorubicin in relationship to clinical 
outcome. In the 54 selected genes we investigated SNPs that have previously associated 
with functional changes. For completeness, we covered the selected genes with tag SNPs 
to analyze the whole gene with a minimal set of SNPs. In the 177 patients, five variants 
were identified in FasL, MSH2, CASP3, ABCC5 and CYP3A4 to be associated with 5-year 
progression free survival (PFS). Risk stratification based on the combined effects of the risk 
alleles showed a significant improvement of 5-year PFS. Patients that carried no or only 
one risk allele had a 5-year PFS of 100% compared to a 5-year PFS of 84.4% for carriers of 
2 or 3 risk alleles, 66.7% PFS if a patient carried 4-5 alleles and a 5-years PFS of 41.8% for 
patients with >5 risk alleles (p<0.001). The pharmacogenetic risk factors identified in this 
study might be useful to predict treatment outcome and to stratify patients immediately 
after diagnosis and offer the possibility to improve treatment and outcome.
A discussion of the studies of this thesis and future research perspectives can be found in 
chapter 9. 
Samenvatt ing
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In hoofdstuk 3 bestudeerden we of er bepaalde trends in overleving als ook in lange 
termijn gevolgen te identificeren zijn in kinderen met een osteosaarcoom. Hiervoor in-
cludeerden we 130 kinderen, welke van 1979 tot 2008 behandeld zijn voor een osteosar-
coom. Deze periode van 30 jaar werd opgesplitst in 3 periodes waarin nieuwe behandelpro-
tocollen geïmplementeerd werden (1979-1983, 1984-2002 en 2003-2008). Vergelijking 
van de verschillende periodes liet een verbetering van overleving van 58.6% van kinderen 
behandeld in de periode 1979-1983 naar 78.6% van kinderen behandeld in de periode 
2003-2008 (p=0.13) zien. Het verschil in overleving kon niet verklaard worden door het 
gebruik van andere cytostatica dan wel andere cumulatieve doseringen. Op basis van de 
analyses werd dan ook geconcludeerd dat niet de chemotherapie maar de verbeterde 
supportive care als belangrijkste factor gezien moet worden wat heeft bijgedragen aan 
de verbeterde overleving . Verder laat deze studie zien dat er een evident risico is op late 
effecten van de behandeling zoals cardiale problemen en secundaire maligniteiten. 
Hoofdstuk 4 beschrijft een methode om DNA te isoleren uit deels 30 jaar gearchiveerd, 
formaline gefixeerd en ontkalkt weefsel. Het ontwikkelen van deze techniek was nodig 
gezin door de hoge mortaliteit van deze ziekte slechts van een deel van de geïncludeerde 
patiënten DNA aanwezig was. Echter was van alle patiënten tumorweefsel met omringend 
normaal weefsel in vorm van spieren of huid opgeslagen in het pathologische archief. 
Doormiddel van deze, door ons ontwikkelde techniek, zijn wij geslaagd om betrouwbare 
germline DNA van het spier- of huidweefsel te isoleren. 
In hoofdstuk 5 bestudeerden we in een kandidaat gen analyse genetische variaties welke 
invloed kunnen hebben op de eliminatie van methotrexaat (MTX). Hoog gedoseerd meth-
otrexaat is een van de belangrijkste behandelcomponenten in de therapie van osteosarco-
men. Echter ervaren patiënten veel bijwerkingen door de in de geneeskunde uitzonderlijk 
hoge dosering van MTX met 12 g/m2. In totaal werden 640 giften van hoog gedoseerde 
MTX geëvalueerd. MTX-geïnduceerde toxiciteit graad 3 of 4 werd gezien in 41.8% van de 
patiënten. Vier polymorfismen lieten een associatie met MTX plasma spiegels zien met een 
p-waarde van <0.10: ABCC2 c.3972C>T, AMPD1 c.34C>T, ITPA c.94C>T en GSTT1del. As-
sociatie analyse van deze vier polymorfismen met MTX-geïnduceerde toxiciteit liet echter 
geen significante associatie zien. Concluderend hebben wij aanwijzingen gevonden dat ge-
netische variaties een invloed hebben op de hoogte van de MTX spiegel. Echter waren deze 
varianten niet geassocieerd met een verhoogd risico op MTX-gerelateerde bijwerkingen. 
In hoofdstuk 6 evalueerden we de rol van het MTHFR c.677C>T polymorfisme met be-
trekking tot het ontwikkelen van MTX-geïnduceerde levertoxiciteit. Hiervoor analyseerden 
we een cohort van 98 kinderen met een osteosarcoom dan wel acute lymfatische leukemie 
welke allen behandeld waren met hoog gedoseerde MTX. We vonden en 1.8 keer verhoogd 
risico op het ontwikkelen van levertoxiciteit bij patiënten met een T versus een C allel (95% 
CI 1.0-3.2, p=0.04). Deze bevinding werd niet bevestigd in een meta-analyse van zeven 
Het osteosarcoom is de meest voorkomende bottumor op de kinder- en adolescenten-
leeftijd. Desondanks is het een niet vaak voorkomende ziekte met een incidentie van 
slechts 35-45 nieuwe gevallen per jaar in Nederland. Door de invoering van pre- en post-
operatieve chemotherapie is de overleving van patiënten met een osteosarcoom sterk 
verbeterd van 20-30% in de jaren zeventig naar ongeveer 60-70% tegenwoordig. Echter 
ondanks deze duidelijke verbetering, reageert nog steeds een groot deel van de patiënten 
onvoldoende op de behandeling en overlijdt. De reden hiervoor heeft mogelijk te maken 
met de ongevoeligheid van de tumor van deze patiënten voor de cytostatica die gegeven 
worden. Verschillen in de gevoeligheid op een behandeling kunnen worden veroorzaakt 
door omgevingsfactoren en genetische factoren. Bij deze genetische factoren gaat het 
vaak om frequent aanwezige varianten in genen coderend voor enzymen, transporterts of 
receptoren betrokken bij farmacokinetiek, farmacodynamiek of pathogenese van de ziekte. 
Deze frequent voorkomende genetische varianten worden ook ‘polymorfismen’ genoemd. 
Ongeveer 3-5% van de polymorfismen beïnvloeden het functioneren van het gen, maar 
deze invloed lijdt niet tot grote problemen voor de gezonde mens onder normale omstan-
digheden. Echter tijdens een behandeling kunnen deze polymorfismen wel van invloed op 
het farmacologische metabolisme van de medicamenten die gegeven worden, wat kan 
leiden tot meer bijwerkingen of het uitblijven van een behandelingsresultaat. Meer inzicht 
in de mechanismen die leiden tot ongevoeligheid voor de behandeling en de genetische 
factoren of genetische varianten die daarbij een rol spelen zou kunnen leiden tot een 
meer effectieve behandeling van patiënten met een slechte respons. Bij farmacogenetica 
worden de genetische varianten van genen die coderen voor enzymen, drug transporters 
of receptoren die betrokken zijn bij het farmacologische metabolisme bestudeerd en geb-
ruikt om die patiënten at risk voor bijwerkingen of ongevoeligheid voor de behandeling te 
identificeren. In dit promotietraject was het doel het verrichten van een farmacogenetische 
studie om een genetisch profiel te kunnen definiëren waarmee die patiënten at risk voor 
een slechte response op de chemotherapie en  daarmee een slechte prognose ten aanzien 
van survival te kunnen definiëren. 
Hoofdstuk 1 omvat een algemene introductie en beschrijft de huidige behandeling van 
patiënten met een osteosarcoom, de relatie tussen prognostische factoren en overleving, 
en de huidige kennis betreffende de rol van farmacogenetica in de behandeling van pa-
tiënten met kanker. Tevens worden de doelen en inhoud van dit proefschrift beschreven. 
Hoofdstuk 2 beschrijft de analyse naar de rol van leeftijd op moment van diagnose op de 
overlevingskans van patiënten met een osteosarcoom. In totaal werden 102 patiënten geïn-
cludeerd voor deze studie. Voor de gehele groep was de 5-jaars overleving 53.5%. We vonden 
een significante associatie tussen leeftijd op moment van diagnose en de overlevingskans. 
Patiënten jonger dan 10 jaar hadden een overleving van 70.6% vergeleken met patiënten 
tussen 11 en 19 jaar met een overleving van 52.5% en patiënten ouder dan 20 jaar met een 
overleving van slechts 33.3% (p=0.002). 
144 Samenvatting
studies met 1044 patiënten; de OR voor 677 T versus C allel was 1.1 (95% CI 0.84-1.5, 
p=0.25). We concludeerden dat in patiënten met kanker, het MTHFR c.677C>T polymorf-
isme geen duidelijke rol speelt in het ontwikkelen van MTX-geïnduceerde levertoxiciteit.
In hoofdstuk 7 evalueerden we polymorfismen in het TPMT en COMT gen welke in een 
onlangs gepubliceerd artikel in Nature Genetics in verbinding werden gebracht het ontwik-
kelen van cisplatin-geïnduceerde ototoxiciteit. Hiervoor analyseerden we twee onafhanke-
lijke groepen van patiënten met een osteosarcoom, respectievelijk 110 en 38 patiënten en 
verrichtten een meta-analyse samen met alle tot nu gepubliceerde studies op dit gebied 
van in totaal 664 patiënten met kanker. Enkel het rs4646316 polymorfisme in het COMT 
gen liet een significante associatie zien met het ontwikkelen van ototoxiciteit (OR A versus 
T allele: 1.5, 95% CI: 1.14-1.97, p=0.003). Het effect was echter veel kleiner dan in het 
gepubliceerde artikel in Nature Genetics. Hieruit concludeerden we, dat de invloed van 
polymorfismen in het TPMT dan wel COMT gen op het ontwikkelen van cisplatin-geïndu-
ceerde ototoxiciteit minder beduidend is dan eerst aangenomen. 
In hoofdstuk 8 werden  genetische variaties van genen betrokken in de metabole path-
ways van cisplatin en doxorubicin  bestudeerd in relatie tot de progressievrije overleving 
(PFS) bij patiënten met een osteosarcoom. We analyseerden 381 polymorfismen in 54 
genen in 177 patiënten met gebruikmaking van een Illumina Bead Array systeem. De 
sterkste associaties met PFS werden gevonden voor polymorfismen in FasL, MSH2, CASP3, 
ABCC5 en CYP3A4. Gebaseerd op de aanwezigheid van deze genetische factoren werd per 
patiënt een genetische score berekend. Patiënten zonder of enkel een risico allel hadden 
een 5-jaars PFS van 100% vergeleken met een 5-jaar PFS van 84.4% in patiënten met 2 of 
3 risico allelen, 66.7% in patiënten met 4 of 5 risico allelen en 41.8% in dragers van meer 
dan 5 risico allelen. Met deze studie hebben wij genen aan kunnen geven welke mogelijk 
essentieel zijn voor de uitkomst in de behandeling van het osteosarcoom. 
Hoofdstuk 9 geeft een algemene discussie waarin de conclusies van de verschillende 
studies worden samengevat en wordt ingegaan op wat dit betekent voor vervolgonderzoek 
bij patiënten met een osteosarcoom. 
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